[go: up one dir, main page]

AU2008205116A1 - Macrocyclic hepatitis C protease inhibitors - Google Patents

Macrocyclic hepatitis C protease inhibitors Download PDF

Info

Publication number
AU2008205116A1
AU2008205116A1 AU2008205116A AU2008205116A AU2008205116A1 AU 2008205116 A1 AU2008205116 A1 AU 2008205116A1 AU 2008205116 A AU2008205116 A AU 2008205116A AU 2008205116 A AU2008205116 A AU 2008205116A AU 2008205116 A1 AU2008205116 A1 AU 2008205116A1
Authority
AU
Australia
Prior art keywords
cycloalkyl
alkyl
substituted
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008205116A
Inventor
Juan Manuel Betancort
David Alan Campbell
Michael E. Hepperle
David T. Winn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phenomix Corp
Original Assignee
Phenomix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomix Corp filed Critical Phenomix Corp
Publication of AU2008205116A1 publication Critical patent/AU2008205116A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Description

WO 2008/086161 PCT/US2008/050208 MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS 5 CROSS-REFERENCE TO RELATED APPLICATION This claims the priority of U.S. Ser. No. 60/883,946, filed Jan. 8, 2007, which is incorporated herein by reference in its entirety. BACKGROUND 10 Hepatitis C virus ("HCV") is the causative agent for hepatitis C, a chronic infection characterized by jaundice, fatigue, abdominal pain, loss of appetite, nausea, and darkening of the urine. HCV, belonging to the hepacivirus genus of the Flaviviriae family, is an enveloped, single-stranded positive-sense RNA-containing virus. The long-term effects of hepatitis C infection as a 15 percentage of infected subjects include chronic infection (55-85%), chronic liver disease (70%), and death (1-5%). Furthermore, HCV is the leading indication for liver transplant. In chronic infection, there usually presents progressively worsening liver inflammation, which often leads to more severe disease states such as cirrhosis and hepatocellular carcinoma. 20 The HCV genome (Choo et al., Science 1989, 244, 359-362; Simmonds et al., Hepatology 1995, 21, 570-583) is a highly variable sequence exemplified by GenBank accession NC_004102 as a 9646 base single-stranded RNA comprising the following constituents at the parenthetically indicated positions: 5' NTR (i.e., non-transcribed region) (1-341); core protein (i.e., viral capsid 25 protein involved in diverse processes including viral morphogenesis or regulation of host gene expression) (342-914); El protein (i.e., viral envelope) (915-1490); E2 protein (i.e., viral envelope) (1491-2579); p 7 protein (2580 2768); NS2 protein (i.e., non-structural protein 2) (2769-3419); NS3 protease (3420-5312); NS4a protein (5313-5474); NS4b protein (5475-6257); NS5a 30 protein (6258-7601); NS5b RNA-dependent RNA polymerase (7602-9372); and 3' NTR (9375-9646). Additionally, a 17-kDalton -2/+1 frameshift protein, "protein F", comprising the joining of positions (342-369) with (371-828) may provide functionality originally ascribed to the core protein. 1 WO 2008/086161 PCT/US2008/050208 The NS3 (i.e., non-structural protein 3) protein of HCV exhibits serine protease activity, the N-terminus of which is produced by the action of a NS2 NS3 metal-dependent protease, and the C-terminus of which is produced by auto-proteolysis. The HCV NS3 serine protease and its associated cofactor, 5 NS4a, process all of the other non-structural viral proteins of HCV. Accordingly, the HCV NS3 protease is essential for viral replication. Several compounds have been shown to inhibit the hepatitis C serine protease, but all of these have limitations in relation to the potency, stability, selectivity, toxicity, and/or pharmacodynamic properties. Such compounds have 10 been disclosed, for example, in published U.S. Patent Application Nos. 2004/0266731, 2002/0032175, 2005/0137139, 2005/0119189, and 2004/9977600A1, and in published PCT patent applications WO 2005/037214 and WO 2005/035525. 15 SUMMARY The present invention provides macrocyclic compounds of Formula X that are adapted to inhibit the viral protease NS3 of the Hepatitis C Virus (HCV). The compounds of Formula X are adapted to bind to, and thus block the action of, an HCV-encoded protease enzyme that is required by the virus for the 20 production of intact, mature, functional viral proteins from the viral polyprotein as translated from the viral RNA, and therefore for the formation of infectious particles, and ultimately for viral replication. The compounds of the invention are believed to act as mimics or analogs of the peptide domain immediately N terminal of the substrate site where the viral protease cleaves its native substrate 25 viral polyprotein. Embodiments of the inventive compounds are analogs of peptides, comprising peptide (amide) bonds, inter alia, wherein a macrocyclic ring joins portions of the molecule, and wherein the group analogous to the C-terminus of a peptide is a carboxamide or analog thereof which can be unsubstituted or 30 substituted with a range of substituents. 2 WO 2008/086161 PCT/US2008/050208 Accordingly, embodiments of the invention include a compound of Formula X: z X1Y Rla R2a R1 NR2 R T K V _W NIID N \HN--Rb DNN M O M (CHR 6 ) X and stereoisomers, solvates, tautomers, prodrugs, salts, pharmaceutically 5 acceptable salts, and mixtures thereof, wherein: Ra and Rb at each occurrence are independently H, OR 3 , NR 4 R', alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein 10 any carbon atom can be substituted with J; or, Ra and R , together with a nitrogen atom to which they are bound, form a 3-8 membered heterocyclic ring which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered heterocyclic ring can contain 1-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(O) 2 , wherein the 3-8 membered 15 heterocyclic ring can be fused with a substituted or unsubstituted, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any combination thereof; R', R a, R2 and R 2 a are independently H or alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, 20 heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J;
R
3 , R 4 and R 5 are independently H or alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, 3 WO 2008/086161 PCT/US2008/050208 heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; or R 4 and R , together with a nitrogen atom to which they are bound, form a 3-8 membered heterocyclic ring which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered heterocyclic ring can contain 5 1-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(O) 2 , wherein the 3-8 membered heterocyclic ring can be fused with a cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any combination thereof; D is CH 2 , CH or N; 10 when D is CH 2 , then W, V, K and T are absent; when D is CH, then W is C( R 6
)
2 , 0, S, or NR 7 , and V, K, and T are as defined below; when D is N then W, V and K are bonds, the bonds taken together forming a single bond, T is as defined below, such that T is bonded directly to D; 15 wherein R 6 is independently at each occurrence hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; or wherein two R6 groups together 20 with a carbon atom to which they are bond form a 3-8 membered cycloalkyl, which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered cycloalkyl can contain 1-3 heteroatoms selected from the group consisting of 0,
NR
7 , S, S(O), and S(0) 2 , wherein the 3-8 membered cycloalkyl can be fused with a cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any 25 combination thereof;
R
7 is independently at each occurrence hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can 30 be substituted with J, or aralkanoyl, heteroaralkanoyl, C(O)R', SO 2 R' or carboxamido, wherein any aralkanoyl or heteroaralkanoyl is substituted with 0-3 J groups;
R
8 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, 4 WO 2008/086161 PCT/US2008/050208 heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; m is 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; 5 pis1,2,3,or4; M is 0, S, S(O), S(O) 2 , C( R ) 2 or N(R7); J is halogen, R', OR', CN, CF 3 , OCF 3 , 0, S, C(O), S(O), methylenedioxy, ethylenedioxy, (CH 2
)
0
-
2
N(R')
2 , (CH 2
)
0
-
2 SR', (CH 2
)
0
-
2 S(O)R', (CH 2
)
0
-
2
S(O)
2 R',
(CH
2
)
0
-
2
S(O)
2
N(R')
2 , 10 (CH 2
)
0
-
2
SO
3 R', (CH 2
)
0
-
2 C(O)R', (CH 2
)
0
-
2 C(O)C(O)R', (CH 2
)
0
-
2
C(O)CH
2 C(O)R',
(CH
2
)
0
-
2 C(S)R',
(CH
2
)
0
-
2 C(O)OR', (CH 2
)
0
-
2 0C(O)R', (CH 2
)
0
-
2
C(O)N(R')
2 , (CH 2
)
0
-
2 0C(O)N(R') 2 ,
(CH
2
)
0
-
2
C(S)N(R')
2 , (CH 2
)
0 2 NH-C(O)R', (CH 2
)
0
-
2 N(R')N(R')C(O)R',
(CH
2
)
0
-
2 N(R')N(R')C(O)OR', (CH 2
)
0
-
2
N(R')N(R')CON(R')
2 , (CH 2 )o- 2
N(R')SO
2 R', 15 (CH 2
)
0
-
2
N(R')SO
2
N(R')
2 , (CH 2
)
0
-
2 N(R')C(O)OR', (CH 2
)
0
-
2 N(R')C(O)R', (CH 2
)
0 2 N(R')C(S)R', (CH 2
)
0
-
2
N(R')C(O)N(R')
2 , (CH 2 )o- 2
N(R')C(S)N(R')
2 , (CH 2
)
0 2 N(COR')COR', (CH 2
)
0
-
2 N(OR')R', (CH 2
)
0
-
2
C(=NH)N(R')
2 , (CH 2
)
0 2 C(O)N(OR')R', or (CH 2
)
0
-
2 C(=NOR')R'; wherein, each R' is independently at each occurrence hydrogen, (Ci-C 1 2 )-alkyl, 20 (C 2
-C
12 )-alkenyl, (C 2
-C
12 )-alkynyl, (C 3 -Cio)-cycloalkyl, (C 3 -Cio)-cycloalkenyl,
[(C
3 -Cio)cycloalkyl or (C3-Cio)-cycloalkenyl]-[(C 1
-C
1 2 )-alkyl or (C 2 -C12) alkenyl or (C 2
-C
12 )-alkynyl], (C 6 -Cio)-aryl, (C 6 -Ci)-aryl-[(CI-C 1 2 )-alkyl or (C 2 C 1 2 )-alkenyl or (C 2
-C
12 )-alkynyl], (C 3 -Cio)-heterocyclyl, (C 3 -Cio)-heterocyclyl
[(C
1
-C
1 2 )-alkyl or (C 2
-C
1 2 )-alkenyl or (C 2
-C
12 )-alkynyl], (C 5 -Cio)-heteroaryl, or 25 (C 5 -Cio)-heteroaryl-[(C1-CI 2 )-alkyl or (C 2
-C
1 2 )-alkenyl or (C 2
-C
1 2 )-alkynyl], wherein R' is substituted with 0-3 substituents selected independently from J; or, when two R' are bound to a nitrogen atom or to two adjacent nitrogen atoms, the two R' groups together with the nitrogen atom or atoms to which they are bound can form a 3- to 8-membered monocyclic heterocyclic ring, or an 8- to 30 20-membered, bicyclic or tricyclic, heterocyclic ring system, wherein any ring or ring system can further contain 1-3 additional heteroatoms selected from the group consisting of N, NR 7 , 0, S, S(O) and S(0) 2 , wherein each ring is substituted with 0-3 substituents selected independently from J; 5 WO 2008/086161 PCT/US2008/050208 wherein, in any bicyclic or tricyclic ring system, each ring is linearly fused, bridged, or spirocyclic, wherein each ring is either aromatic or nonaromatic, wherein each ring can be fused to a (C 6 -CIo)aryl, (C 5
-C
10 ) heteroaryl, (C 3 -Cio)cycloalkyl or (C 3
-C
1 0) heterocyclyl; 5 L is 0, S, C 2 , C 2
H
2 or C2H4; V is a bond, C( R' 0
)
2 , C(O), S(O), or S(O)2; K is a bond, 0, S, C(0), S(0), S(0) 2 , S(0)(NR 7 ), or N(R7); provided that when V and K are both bonds, they form together a single bond; 10 R' 0 is independently at each occurrence hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or, two R 1 0 groups together with a carbon atom to which they are bound form a 3-8 membered cycloalkyl, which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered cycloalkyl can contain 1-3 15 heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(O) 2 , wherein the 3-8 membered cycloalkyl can be fused with a cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any combination thereof; T is R", alkyl-R", alkenyl-R 11 , alkynyl-R", OR", N(R" )2, C(O) R", or C(=NOalkyl) R 11 ; 20 R" is independently at each occurrence hydrogen, alkyl, aryl, aralkyl, alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any R" except hydrogen is substituted with 0-3 J groups, or a first R" and a 25 second R" together with a nitrogen atom to which they are bound form a mono or bicyclic ring system substituted with 0-3 J groups and can contain 1-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(O) 2 ; and when W is C( R6 ) 2, a bond, or absent; 30 X is a bond, 0, S, CH( R 6 ) or N(R7; Y is a bond, CH(R 6 ), C(O), C(O)C(O), S(O), S(O) 2 , or S(O)(NR 7 ); provided that when both X and Y are bonds, they together form a single bond; 6 WO 2008/086161 PCT/US2008/050208 Z is: a) hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, OR 9 , or N(R9)2, wherein any carbon atom is unsubstituted or is substituted with J, and wherein 5 R 9 is independently at each occurrence hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, or heteroarylalkyl, or two R9 groups together with a nitrogen atom to which they are bound can form together with the nitrogen atom a 5-11 membered mono- or bicyclic heterocyclic ring 10 system substituted with 0-3 J groups and further including 0-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(O) 2 ; or b) a substituted aryl or heteroaryl group; wherein any aryl or heteroaryl is substituted with 1-3 J groups; 15 or c) a group of the formula: R12P R13 R18OP N h R1
R
1 9 )
R
17
R
14
R
15
R
16 wherein 12 13 14 1 8 1 20 R , R , R4, R", R" and R'9 are independently hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R1 2 and R' or R 1 4 and R" or R" 8 and R' 9 , 25 together with a carbon atom to which they are attached, form a C 3
-
6 cycloalkyl group; R1 6 and R 1 7 are independently hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl] [alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, 7 WO 2008/086161 PCT/US2008/050208 heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R1 6 and R 7 together with the atoms to which they are attached form a fused substituted or unsubstituted aryl or heteroaryl group; g is 0-1; and 5 h is 0-2; or d) a group of the formula: S( R 12 R 13 N R 14 h R 20 R 15 R 23 R21 R 22 wherein 10 g is 0-2; and h is 0-2; R1 2 , R, R 1 4 , and R1 5 are independently at each occurrence hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, 15 aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, 12 1315 heteroarylalkyl, or heteroarylalkenyl group; or R and R" or R 4 and R , together with a carbon atom to which they are attached, form a C 3
.
6 cycloalkyl group; R2, R , R2, R2 are independently H, F, Cl, Br, I, CN, CF 3 , 20 OCF 3 , OR 2 4 , (CH 2 )qOR24, O(CH2)qOR24 , NR5R26, (CH 2 )qNR 2R26
O(CH
2 )qNR 2 5
R
2 6 , SR 2 4 , (CH 2 )qSR 24 , O(CH 2 )qSR24, C(O)R24, (CH 2 )qC(O)R24
O(CH
2 )qC(O)R 2 4 , C(O)OR24, (CH 2 )qC(O)OR 24, O(CH 2 )qC(O)OR24
NR
27
C(O)R
24 , (CH 2 )qNR 27 C(O)R 24, O(CH 2 )qNR C(O)R24, C(O)NR2R26,
(CH
2 )qC(O)NR R26, O(CH 2 )qC(O)NR 2 5
R
2 6 , NR 27 C(O)NR R26 25 (CH 2 )qNR 2 ' C(O)NRR 2 6 , O(CH 2 )qNR 27
C(O)NR
5
R
26 , OC(O)NR 25
R
26
(CH
2 )qOC(O)NR R6, O(CH 2 )qOC(O)NRR26 , NR C(O)OR24
(CH
2 )qNR 27
C(O)OR
2 4 , O(CH 2 )qNR 27 C(O)OR24 , NR SO 2 R24 8 WO 2008/086161 PCT/US2008/050208
(CH
2 )qNR2SO 2 R 2, O(CH 2 )qNR27SO 2
R
24 , S0 2
NR
5
R
26 , (CH 2 )qSO 2 NR R26, or
O(CH
2 )qSO 2 NR25R 26 , or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, 5 heteroarylalkyl, or heteroarylalkenyl group, q is 1, 2, 3, 4, 5, or 6; and each R 24 , R 25 , R 26 , and R 27 is independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, arylalkenyl, heterocyclyl, 10 heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R 25 and R 26 together with a nitrogen atom to which they are attached form a 3-7 membered heterocyclic ring substituted with 0-3 J groups, that further comprises 0-3 additional heteroatoms selected from the groups consisting of 0, NR 7 , S, S(O), and S(0) 2 ; 15 or e) a group of the formula R 12
R
1 3 N R 14 h R 15 9 N R 23 R 21 R22. wherein g is 0-2; and 20 h is 0-2; 12 13 14 15 2123fie in() R , R , R14 R , R21, R2 and R2 are as defined in (d); or 25 9 WO 2008/086161 PCT/US2008/050208 f) a group of the formula R 12
R
13 N R 14 h
R
15 N R23N R 22. wherein 5 g is 0-2; and h is 0-2; R 12, R13 R14, R", R , R2 and R2 are as defined in (d); and wherein a wavy line signifies a point of attachment; and, 10 when W is NR 7 , O or S: X is 0, CH 2 , or NR'; Y is C(R6 ) 2 or absent; and Z is a substituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, 15 heterocyclylalkenyl, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, arylamino, heteroaryl, or heteroarylalkyl; wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, arylamino, heteroaryl, or heteroarylalkyl is substituted with 20 1-3 J groups, provided that K and V are both bonds, taken together forming a single bond such that T is bonded directly to W, T is not C(O)R"; or, X is 0; Y is C(O); 25 10 WO 2008/086161 PCT/US2008/050208 Zis aa) a group of the formula N R12 R 13 N R 14 h R 20 R 1
R
23
R
21 R 22. 5 wherein g is 0-2; and h is 0-2; R', R' , R 4 , and R' 5 are independently at each occurrence hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, 10 cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, 12 13 14 15 heteroarylalkyl, or heteroarylalkenyl group; or R and R or R' 4 and R together with a carbon atom to which they are attached, form a C 3
-
6 cycloalkyl group; 15 R20, R21, R 2 , R 3 are independently H, F, Cl, Br, I, CN, CF 3 ,
OCF
3 , OR24, (CH 2 )qOR24, O(CH2)qOR24 , NR R26, (CH 2 )qNR R26,
O(CH
2 )qNR 2 5
R
2 6 , SR 24 , (CH 2 )qSR 24 , O(CH 2 )qSR 2 4 , C(O)R 2 4 , (CH 2 )qC(O)R 2 4 ,
O(CH
2 )qC(O)R 24 , C(O)OR24, (CH 2 )qC(O)OR 24 , O(CH 2 )qC(O)OR24
NR
27 C(O)R24, (CH 2 )qNR C(O)R 24 , O(CH 2 )qNR2C(O)R 24, C(O)NR R26 20 (CH 2 )qC(O)NR2R26, O(CH 2 )qC(O)NR 25
R
26 , NR 27 C(O)NR R26
(CH
2 )qNRC(O)NR 5
R
26 , O(CH 2 )qNRC(O)NR 2
R
26 , OC(O)NR R26
(CH
2 )qOC(O)NR R26, O(CH 2 )qOC(O)NRR26 , NR C(O)OR24
(CH
2 )qNR 27
C(O)OR
2 4 , O(CH 2 )qNR 2 C(O)OR24, NR27 SO 2 R24
(CH
2 )qNRSO 2
R
24 , O(CH 2 )qNR 2
SO
2
R
24 , SO 2
NRR
26 , (CH 2 )qSO 2 NR2R26, or 25 O(CH 2 )qSO 2 NR2R26, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, 11 WO 2008/086161 PCT/US2008/050208 aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group, q is 1, 2, 3, 4, 5, or 6; and each R24 , R , R 26 , and R 2 7 is independently hydrogen, or a 5 substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, arylalkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R 25 and R 26 together with a nitrogen atom to which they are attached form a 3-7 membered heterocyclic ring substituted with 0-3 J 10 groups, that further comprises 0-3 additional heteroatoms selected from the groups consisting of 0, NR 7 , S, S(O), and S(0) 2 ; or bb) a group of the formula R R13 N R14 R h R 15 9/ N
R
23 R21 15 R22 wherein g is 0-2; and h is 0-2; 12 13 14 15 20 22 23 R R R R", R20,R andR areas defined in (aa); 20 25 12 WO 2008/086161 PCT/US2008/050208 or cc) a group of the formula N R12 R 13 R14 h gRo R 15 N R 23N R 22. 5 wherein g is 0-2; and h is 0-2; R1, R1 , R14, R", R20, R2 and R 23 are as defined in (c); wherein a wavy line signifies a point of attachment. 10 The invention further provides a method for synthesis of a compound of Formula X. The invention further provides a pharmaceutical composition comprising a compound of Formula X and a suitable excipient. The invention further provides a pharmaceutical combination comprising 15 a compound of Formula X in a therapeutically effective amount and a second medicament in a therapeutically effective amount. The pharmaceutical combination of the invention may be formulated as a pharmaceutical composition of the invention. The present invention further provides a method of treatment of a HCV 20 infection in a patient in need thereof, or in a patient when inhibition of an HCV viral protease is medically indicated, comprising administering a therapeutically effective amount of a compound of Formula I to the patient, or a pharmaceutical combination to the patient. 13 WO 2008/086161 PCT/US2008/050208 DETAILED DESCRIPTION OF THE INVENTION Definitions The terms "HCV NS3 serine protease", "HCV NS3 protease", "NS3 5 serine protease", and "NS3 protease" denote all active forms of the serine protease encoded by the NS3 region of the hepatitis C virus, including all combinations thereof with other proteins in either covalent or noncovalent association. For example, other proteins in this context include without limitation the protein encoded by the NS4a region of the hepatitis C virus. 10 Accordingly, the terms "NS3/4a" and "NS3/4a protease" denote the NS3 protease in combination with the HCV NS4a protein. The term "other type(s) of therapeutic agents" as employed herein refers to one or more antiviral agents (other than HCV NS3 serine protease inhibitors of the invention). 15 "Subject" as used herein, includes mammals such as humans, non-human primates, rats, mice, dogs, cats, horses, cows and pigs. The term "treatment" is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes administering a compound of the present invention to prevent the onset of the 20 symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder. "Treating" within the context of the instant invention means an alleviation of symptoms associated with a disorder or disease, or inhibition of further progression or worsening of those symptoms, or prevention or 25 prophylaxis of the disease or disorder. Thus, treating a hepatitis C viral infection includes slowing, halting or reversing the growth of the virus and/or the control, alleviation or prevention of symptoms of the infection. Similarly, as used herein, an "effective amount" or a "therapeutically effective amount" of a compound of the invention refers to an amount of the compound that alleviates, in whole or in 30 part, symptoms associated with the disorder or condition, or halts or slows further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disorder or condition. In particular, a "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result by inhibition of HCV 14 WO 2008/086161 PCT/US2008/050208 NS3 serine protease activity. A therapeutically effective amount is also one in which any toxic or detrimental effects of compounds of the invention are outweighed by the therapeutically beneficial effects. For example, in the context of treating HCV infection, a therapeutically effective amount of a HCV NS3 5 serine protease inhibitor of the invention is an amount sufficient to control HCV viral infection. All chiral, diastereomeric, racemic forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. Compounds used in the present invention include enriched or resolved optical 10 isomers at any or all asymmetric atoms as are apparent from the depictions. Both racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these are all within the scope of the invention. 15 The term "amino protecting group" or "N-protected" as used herein refers to those groups intended to protect an amino group against undesirable reactions during synthetic procedures and which can later be removed to reveal the amine. Commonly used amino protecting groups are disclosed in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New 20 York, NY, (3rd Edition, 1999). Amino protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2 bromoacetyl, trifluoroacetyl, trichloroacetyl, o-nitrophenoxyacetyl, a chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like; 25 alkoxy- or aryloxy-carbonyl groups (which form urethanes with the protected amine) such as benzyloxycarbonyl (Cbz), p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2 nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4 dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4 30 dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5 dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p biphenylyl)- 1 -methylethoxycarbonyl, a,a-dimethyl-3,5 dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, 15 WO 2008/086161 PCT/US2008/050208 methoxycarbonyl, allyloxycarbonyl (Alloc), 2,2,2-trichloroethoxycarbonyl, 2 trimethylsilylethyloxycarbonyl (Teoc), phenoxycarbonyl, 4 nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl (Fmoc), cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, 5 phenylthiocarbonyl and the like; aralkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl groups such as trimethylsilyl and the like. Amine protecting groups also include cyclic amino protecting groups such as phthaloyl and dithiosuccinimidyl, which incorporate the amino nitrogen into a heterocycle. Typically, amino protecting groups include formyl, acetyl, benzoyl, 10 pivaloyl, t-butylacetyl, phenylsulfonyl, Alloc, Teoc, benzyl, Fmoc, Boc and Cbz. It is well within the skill of the ordinary artisan to select and use the appropriate amino protecting group for the synthetic task at hand. In general, "substituted" refers to an organic group as defined herein in which one or more bonds to a hydrogen atom contained therein are replaced by a 15 bond to non-hydrogen or non-carbon atoms such as, but not limited to, a halogen (i.e., F, Cl, Br, and I); an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as 20 amines, hydroxylamines, N-oxides, hydrazides, azides, and enamines; and other heteroatoms in various other groups. Substituted alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl groups as well as other substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a 25 heteroatom such as, but not limited to, oxygen in carbonyl (oxo), carboxyl, ester, amide, imide, urethane, and urea groups; and nitrogen in imines, hydroxyimines, oximes, hydrazones, amidines, guanidines, and nitriles. When a group is defined as being substituted, it is understood that the substitution is "chemically feasible", that is, that the substitution can be made 30 without violating any of the well-known rules of chemical bonding known to those of skill in the art. For example, if a particular substitution of a chemical group would result in the presence of a pentavalent carbon atom in the structure, it is understood that the particular substitution of the chemical group would not be contemplated. 16 WO 2008/086161 PCT/US2008/050208 When a substituent is expressed in a combinatorial manner, as in a Claim, for example "[cycloalkyl or cycloalkenyl]-[alkyl or alkenyl]", what is meant is all possible combinations of the options in the first alternative and the options in the second alternative; thus the above example includes 5 cycloalkylalkyl, cycloalkylalkenyl, cycloalkenylalkyl, and cycloalkenylalkenyl. The term "heteroatoms" as used herein refers to non-carbon and non hydrogen atoms, and is not otherwise limited. Typical heteroatoms are N, 0, and S. When sulfur (S) is referred to, it is understood that the sulfur can be in any of the oxidation states in which it is found, thus including sulfoxides (R 10 S(O)-R') and sulfones (R-S(0) 2 -R'), unless the oxidation state is specified; thus, the term "sulfone" encompasses only the sulfone form of sulfur; the term "sulfide" encompasses only the sulfide (R-S-R') form of sulfur. When the phrases such as "heteroatoms selected from the group consisting of 0, NH, NR' and S," or "[variable] is 0, S . . ." are used, they are understood to encompass all 15 of the sulfide, sulfoxide and sulfone oxidation states of sulfur. Substituted ring groups such as substituted aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted aryl, heterocyclyl and heteroaryl groups may also be substituted with alkyl, 20 alkenyl, and alkynyl groups as defined herein. Alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms. Examples of straight chain alkyl groups include those with from 1 to 8 carbon atoms such as 25 methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. Representative substituted alkyl groups may be substituted one or more times with any of the groups listed above, for example, amino, hydroxy, cyano, 30 carboxy, nitro, thio, alkoxy, and halogen groups. Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 17 WO 2008/086161 PCT/US2008/050208 5, 6, or 7. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or 5 branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which may be substituted with, for example, amino, hydroxy, cyano, carboxy, nitro, thio, 10 alkoxy, and halogen groups. The term "cycloalkenyl" alone or in combination denotes a cyclic alkenyl group. The terms "carbocyclic" and "carbocycle" denote a ring structure wherein the atoms of the ring are carbon. In some embodiments, the carbocycle has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms 15 is 4, 5, 6, or 7. Unless specifically indicated to the contrary, the carbocyclic ring may be substituted with as many as N- 1 substituents wherein N is the size of the carbocyclic ring with for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups. A "macrocyclic" molecule, or a "macrocycle," as the term is used herein, 20 refers to a cyclic organic structure wherein a ring has more than about 7 members. Thus, a macrocyclic ring can have 8, 9, 10, 11, 12, 13, 14, or more, members. The atoms making up this ring can be carbon, which can also include heteroatoms such as 0, N, and S (in its various oxidation states, i.e., S, SO, or
SO
2 ). Therefore, a macrocycle can include in the macrocyclic ring carbon 25 chains and peptide (amide) bonds, as well as other moieties such as ethers, sulfides, sulfoxides, sulfones, amines, hydrazines, and the like. (Cycloalkyl)alkyl groups, also denoted cycloalkylalkyl, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above. 30 Alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to vinyl, -CH=CH(CH 3 ), 18 WO 2008/086161 PCT/US2008/050208
-CH=C(CH
3
)
2 , -C(CH 3
)=CH
2 , -C(CH 3
)=CH(CH
3 ), -C(CH 2
CH
3
)=CH
2 , cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others. Cycloalkenyl groups include cycloalkyl groups having at least one 5 double bond between 2 carbons. Thus for example, cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups. (Cycloalkenyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. 10 Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to -C=CH, -C=C(CH 3 ), -C=C(CH 2
CH
3 ), -CH 2 C=CH, 15 -CH 2
C=C(CH
3 ), and -CH 2
C-C(CH
2
CH
3 ) among others. Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms. Thus aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl 20 groups. In some embodiments, aryl groups contain 6-14 carbons in the ring portions of the groups. Although the phrase "aryl groups" includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like), it does not include aryl groups that have other groups, such as alkyl or halogen groups, bonded to one of the ring 25 members. Rather, groups such as tolyl are referred to as substituted aryl groups. Representative substituted aryl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with groups such as those listed above. 30 Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above. Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl. Aralkenyl group are alkenyl groups as defined above in which a hydrogen or 19 WO 2008/086161 PCT/US2008/050208 carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above. Heterocyclyl groups include aromatic and non-aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such 5 as, but not limited to, N, 0, and S. In some embodiments, heterocyclyl groups include 3 to 20 ring members, whereas other such groups have 3 to 15 ring members. The phrase "heterocyclyl group" includes fused ring species including those comprising fused aromatic and non-aromatic groups. The phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited 10 to, quinuclidyl. However, the phrase does not include heterocyclyl groups that have other groups, such as alkyl or halogen groups, bonded to one of the ring members. Rather, these are referred to as "substituted heterocyclyl groups". Heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, 15 isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, 20 tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to, piperidinyl or quinolinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with groups such as those listed above. 25 Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, 0, and S. Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyl, 30 indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Although the phrase "heteroaryl groups" includes fused ring compounds such as indolyl and 20 WO 2008/086161 PCT/US2008/050208 2,3-dihydro indolyl, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as "substituted heteroaryl groups". Representative substituted heteroaryl groups may be substituted one or 5 more times with groups such as those listed above. Additional examples of aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1 anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), 10 furyl (2-furyl, 3-furyl) , indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5 imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2 15 thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2 quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6 20 isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7 benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro benzo[b] furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro 25 benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2 benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl, (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3 dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3 30 dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3 dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 21 WO 2008/086161 PCT/US2008/050208 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2 benzoxazolyl), benzothiazolyl (1 -benzothiazolyl, 2-benzothiazolyl, 4 benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5 5H-dibenz[b,fjazepine (5H-dibenz[b,fjazepin-1-yl, 5H-dibenz[b,fjazepine-2-yl, 5H-dibenz[b,fjazepine-3-yl, 5H-dibenz[b,fjazepine-4-yl, 5H-dibenz[b,fjazepine 5-yl), 10,11 -dihydro-5H-dibenz[b,flazepine (10,11 -dihydro-5H dibenz[b,fjazepine-1-yl, 10,11-dihydro-5H-dibenz[b,fjazepine-2-yl, 10,11 dihydro-5H-dibenz[b,fjazepine-3-yl, 10,11-dihydro-5H-dibenz[b,flazepine-4-yl, 10 10,11 -dihydro-5H-dibenz[b,fjazepine-5-yl), and the like. Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Representative heterocyclyl alkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-3 15 yl methyl, tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl. Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. The term "alkoxy" refers to an oxygen atom connected to an alkyl group 20 as defined above. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like. Examples of branched alkoxy include but are not limited to isopropoxy, sec butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like. Examples of cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, 25 cyclopentyloxy, cyclohexyloxy, and the like. The terms "aryloxy" and "arylalkoxy" refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy. 30 The term "amine" (or "amino") includes primary, secondary, and tertiary amines having, e.g., the formula -NR 2 . Amines include but are not limited to
-NH
2 , alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, aralkylamines, heterocyclylamines and the like. 22 WO 2008/086161 PCT/US2008/050208 The term "amide" (or "amido") includes C- and N-amide groups, i.e.,
-C(O)NR
2 , and -NRC(O)R groups, respectively. Amide groups therefore include but are not limited to carbamoyl groups (-C(O)NH 2 ) and formamide groups (-NHC(O)H). 5 The term "urethane" (or "carbamyl") includes N- and 0-urethane groups, i.e., -NRC(O)OR and -OC(O)NR 2 groups, respectively. The term "sulfonamide" (or "sulfonamido") includes S- and N sulfonamide groups, i.e., -SO 2
NR
2 and -NRSO 2 R groups, respectively. Sulfonamide groups therefore include but are not limited to sulfamoyl groups ( 10 SO 2
NH
2 ). An organosulfur structure represented by the formula -S(O)(NR)- is understood to refer to a sulfoximine, wherein both the oxygen and the nitrogen atoms are bonded to the sulfur atom, which is also bonded to two carbon atoms. The term "amidine" or "amidino" includes groups of the formula 15 -C(NR)NR 2 . Typically, an amidino group is -C(NH)NH 2 . The term "guanidine" or "guanidino" includes groups of the formula
-NRC(NR)NR
2 . Typically, a guanidino group is -NHC(NH)NH 2 . In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the 20 invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if A is described as selected from the group consisting of bromine, chlorine, and iodine, claims for A being bromine and claims for A being bromine and chlorine are fully described. Moreover, where features or aspects of the invention are described in terms of 25 Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any combination of individual members or subgroups of members of Markush groups. Thus, for example, if A is described as selected from the group consisting of bromine, chlorine, and iodine, and B is described as selected from the group consisting of methyl, ethyl, and propyl, 30 claims for A being bromine and B being methyl are fully described. Without wishing to be bound by theory, the standard nomenclature of Schechter & Berger (Biochem. Biophys. Res. Comm., 1967, 27, 157-162) regarding the identification of residues in the polypeptide substrate of serine proteases will be employed herein unless other indicia of identification are 23 WO 2008/086161 PCT/US2008/050208 specifically provided. Within the nomenclature of Schechter & Berger , the residues of the substrate, in the direction from the N-terminal toward the C terminal, are labeled (Pi, ..., P3, P2, P1, P1', P2', Pr' ..., Pj), wherein cleavage is catalyzed between P1 and Pl'. Within the context of this nomenclature, 5 compounds of Formulas X can be considered as mimics of at least the tripeptide P3-Pro-PI, wherein the analog of P1, as a moiety of the macrocyclic structure, is: NH \N--Rb L (CHRp 10 wherein Ra, Rb, L and p are as defined below, wherein the two wavy lines signify two respective points of attachment, and wherein the two points of attachment are ultimately connected to each other via a macrocyclic ring. The inventive compounds include an unsubstituted or a substituted carboxamide moiety or analog thereof at the carboxy terminus of the P1 analog. 15 The present invention provides a compound of Formula X: Z 1Y X R~a R 2a D NH M L
(CHR
6 ) X and stereoisomers, solvates, tautomers, prodrugs, salts, pharmaceutically acceptable salts, and mixtures thereof, wherein: Ra, Rb, R 1 , Ria R 2 , R 2 a, R 3 , R 4 , 24 WO 2008/086161 PCT/US2008/050208 R', D, R6, R', R', R', J, L, M, W, V, K, T, X, Y, Z, p, m and n, and definitions included in the definitions of those groups, are as defined herein. The group attached to the C-terminal analogous portion of the molecule, i.e., Ra NH \N--Rb L (CHR 6 )p wherein the carboxamide or analog thereof defined by the C(O)NRaR group attached to the cycloalkyl ring, includes various embodiments. For example, R" and R can each be hydrogen, in which case the carboxamide is a simple
C(O)NH
2 group. 10 In various other embodiments, one of Ra and Rb is hydrogen and the other is a carbon-linked group, for example, an aralkyl group such as a phenethyl group, providing an N-phenethylcarboxamide, C(O)NHCH 2
CH
2 -(phenyl), wherein the phenyl ring can be unsubstituted, or substituted with J groups. More specifically, the phenethyl group can be a 4-methylphenethyl group, a 3,4 15 dimethylphenethyl group, a 3-chlorophenethyl group, a 4-chlorophenethyl group, a 3-fluorophenethyl group, a 4-fluorophenethyl group, a 2,4 dichlorphenethyl group, a 2,6-dichlorophenethyl group, a 2,4-difluorophenethyl group, or a 2,6-difluorophenethyl group. Or, the carbon linked group can be a heteroarylalkyl group, such as a 4-pyridylethyl group. In various embodiments, 20 mono- and di-substituted carboxamide are provided as are described herein. In various other embodiments, one of Ra and R can be hydrogen, and the other can be an oxygen-linked group, such as an N-benzyloxy group. It is understood that a group of this general type, C(O)NHO(alkyl) is an 0 alkylhydroxamate, so an N-benzyloxycarboxamide is equivalent to an N 25 benzylhydroxamate. Other embodiments include the hydroxamic acid, (C(O)NHOH, as well as in various embodiments O-cycloalkyl, 0-heterocyclyl, 0-aryl, 0-heteroaryl, and O-acyl hydroxamates. In various other embodiments, one of Ra and Rb can be hydrogen, and the other can be a nitrogen-linked group, such as a dialkylamino group. It is 25 WO 2008/086161 PCT/US2008/050208 understood that a group of this general type, C(O)NHN(alkyl) 2 is an acylhydrazide, and thus various acylhydrazide groups are included in embodiments of the inventive compounds. In various other embodiments, Ra and Rb together with the N to which 5 they are bonded form a ring that can include other heteroatoms, can be substituted with substituents as described herein, or can be fused to another ring. For example, Ra and Rb together with the N to which they are bonded can form a hexahydroazepine, such that the C(O)NRaR group is an N-acyl amide thereof. The carboxamide is bonded to a carbon atom that is contained within a 10 cycloalkane ring, the cycloalkane ring itself making up part of the macrocyclic ring that further include a
-(CH
2 )m-M-CH 2
(CH
2 )n-CH 2 -L- group, bond via the L group to the cycloalkane ring, and bonded at the other end to the D atom, thereby forming the macrocycle. The cycloalkane ring can bear an independently selected R6 group on the carbon 15 atom not bonded directly to the L group or to the C(O)NRaRb carboxamide group. The cycloalkane ring has p+2 ring members, including 3-, 4-, 5-, and 6 membered ring sizes in various embodiments. R6 can be, for example, hydrogen at every occurrence, thus providing in various embodiments cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl rings bearing the L group, the 20 carboxamide C(O)NRa R group, and the nitrogen atom forming an amide with the carboxyl group of the proline-analogous pyrrolidine ring. In other embodiments, R 6 can be at one occurrence an alkyl group and at all other occurrences hydrogen, providing, for example, a methylcyclopropyl group when p = 1 . 25 An embodiment of the invention provides a compound of Formula I wherein D is CH 2 and W-K-V-T is absent. In various embodiments compounds of the invention lack the W-V-K-T "N-terminal" tail and the macrocyclic ring is unsubstituted at that position. In another embodiment, D is N and V-K are a bond such that T is bonded 30 directly to D. T can be R 11 , alkyl-R", alkenyl-R", alkynyl-R", OR", N(R 1 )2, C(O) R", or C(=NOalkyl) R"; wherein R 1 is independently at each occurrence hydrogen, alkyl, aryl, aralkyl, alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], heterocyclyl, 26 WO 2008/086161 PCT/US2008/050208 heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any R" except hydrogen is substituted with 0-3 J groups, or a first R and a second R" together with a nitrogen atom to which they are bound form a mono- or bicyclic ring system. In various embodiments, 5 T is C(O)R1 1, providing amide, carbamate (when R" is alkoxy) and urea (when R' is amino, alkylamino or dialkylamino) derivatives of the macrocyclic ring including the nitrogen atom. In another embodiment, D is CH, and W-V-K-T are as defined herein. W can be C(R 6
)
2 , 0, or NR 7 when D is CH. In various embodiments, W is 10 C(R 6
)
2 , for example W is CH 2 . The definitions of X, Y, and Z are the same in embodiments wherein W is C(R 6
)
2 as in embodiments wherein W is a bond (when D is N) or absent (when D is CH 2 ). For example, in various embodiments, X can be a bond, 0, S, CH( R 6 ) or N(R 7 ), Y is a bond, CH(R 6 ), C(O), C(O)C(O), S(O), S(O) 2 , or S(O)(NR 7 ), provided that when both X and Y 15 are bonds, they together form a single bond, and Z can be hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, OR 9 , or N(R 9
)
2 , wherein any carbon atom is unsubstituted or is substituted with J, and wherein R 9 is independently at each occurrence hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, [cycloalkyl or cycloalkenyl] 20 [alkyl or alkenyl], heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, or heteroarylalkyl, or two R 9 groups together with a nitrogen atom to which they are bound can form together with the nitrogen atom a 5-11 membered mono- or bicyclic heterocyclic ring system substituted with 0-3 J groups and further including 0-3 additional heteroatoms selected from the group 25 consisting of 0, NR 7 , S, S(O), and S(0) 2 . In other embodiments, Z can be a substituted aryl or heteroaryl group; wherein any aryl or heteroaryl is substituted with 1-3 J groups. In yet other embodiments, Z can be a group of the formula: R R 1 2 N h
R
1 8 /
R
1 7 R R17 R 1
R
15
R
16 27 WO 2008/086161 PCT/US2008/050208 wherein R1 2 , R1 3 , R1 4 , R", R" 8 and R' 9 can be independently hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or 5 heteroarylalkenyl group; or R1 2 and R" 3 or R1 4 and R" or R1 8 and R1 9 , together with a carbon atom to which they are attached, can form a C 3
.
6 cycloalkyl group, and R16 and R1 7 can be independently hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, 10 heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R1 6 and R 7 together with the atoms to which they are attached form a fused substituted or unsubstituted aryl or heteroaryl group, g is 0-1 and h is 0-2. In various other embodiments, Z is a group of the formula: R12 R13 N
R
13 N R 14 9 h R20 R 15 R23 R 21 R 22 15 wherein g is 0-2 and h is 0-2, and R 1 2 , R 13 ,
R
1 4 , and R 5 can be independently at each occurrence hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or 20 R 1 and R' or R 4 and R , together with a carbon atom to which they are attached, can form a C 3
-
6 cycloalkyl group and R 2 0, R2, R, R2 are as defined above. More specifically, Z can be an unsubstituted isoindoline group, or can be an otherwise unsubstituted isoindolidine group bearing a fluorine atom on the 25 phenyl ring, such as in the R20 position. In various other embodiments, Z is an analog of the isoindolidine group immediately above wherein one of the phenyl ring carbon atoms, such as the 28 WO 2008/086161 PCT/US2008/050208 ring carbon atom bearing R 20 , or the ring carbon atom bearing R , is replaced by a nitrogen atom lacking a substituent. When W is NR 7 , 0, or S, other definitions of X, Y, and Z are applicable. For example, X can be 0, CH 2 , or NR 7 , Y can be C(R 6
)
2 or absent; and Z can be 5 a substituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, arylamino, heteroaryl, or heteroarylalkyl; wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, 10 heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, arylamino, heteroaryl, or heteroarylalkyl is substituted with 1-3 J groups, provided that K and V are both bonds, taken together forming a single bond such that T is bonded directly to W, T is not C(O)R". In various other embodiments, when W is NR7, 0, or S, X can be 0, Y 15 can be C(O), and Z can be a group of the formula R12 R 13 N R 14 h R20 gR R15 1
R
23
R
21 R 22. wherein g is 0-2 and h is 0-2, R , R 3, R 14 , and R1 5 can be independently at each occurrence hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, 20 aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R' and R" or R 14 and R", together with a carbon atom to which they are attached, can form a C3-6 cycloalkyl group, and R20, R, R , R23 can be as defined above. More specifically, Z can be an unsubstituted isoindoline group, or can be 25 an otherwise unsubstituted isoindolidine group bearing a fluorine atom on the phenyl ring, such as in the R20 position, e.g: 29 WO 2008/086161 PCT/US2008/050208 F
N
Various embodiments further provide compounds of Formula X, wherein L is C 2
H
2 , which can be either Z or E substituted (i.e., cis or trans). A compound of Formula X wherein L is C 2
H
2 can be prepared by an olefin 5 metathesis cyclization approach, as described below. The olefinic group can be hydrogenated to provide a compound of Formula X wherein L is C 2
H
4 , or can be dehydrogenated to provide a compound of Formula X wherein L is C 2 , using methods well known in the art. In other embodiments, L can be 0 or S. Such compounds can be 10 prepared by methods well known in the art, for example by formation of an 0 or S anion and subsequent displacement of a leaving group on the chain to which the 0 or S is being coupled. Various embodiments of the invention also provide compounds of Formula X wherein p is 1, i.e,., the ring containing the (CH 2 )p moiety is a 15 cyclopropane ring. In particular, when p is 1, L and the ring together can form a vinylcyclopropane moiety. For example, when L and the ring form a vinylcyclopropane moiety, M can be CH 2 , m = 1, and n = 1, whereby a 5-carbon linker chain forms the macrocyclic ring connecting the end of the vinyl group distal from the cyclopropane to the a-carbon of the aminoacid N-terminal to the 20 proline analog ring. While the inventive compounds include all the stereoisomers of formula X, in a preferred embodiment, the pyrrolidine ring making up the proline analog is substituted with the proline carboxyl group and the 4-substituent (X-Y-Z) being disposed in a trans orientation on the proline ring, thus, a compound of 25 formula XI: 30 WO 2008/086161 PCT/US2008/050208 z xY Rla - R2a Ra T'-,K V W 1-1 N R2 a\ N--Rb DNH H M 0 L (CHR 6 ) Methods/Uses In one aspect, the invention provides methods of inhibiting HCV NS3 5 protease. The methods include contacting the hepatitis C viral serine protease with a compound as described herein. In other embodiments, the methods of inhibiting HCV NS3 protease include administering a compound as described herein to a subject infected with hepatitis C virus. In another aspect, the invention provides methods for treating hepatitis C 10 viral infection. The methods include administering to a subject in need of such treatment an effective amount of a compound of the invention as described herein. As used herein, "a compound" can refer to a single compound or a plurality of compounds. In some embodiments, the methods for treating hepatitis C viral infection include administering to a subject in need of such 15 treatment an effective amount of a composition comprising a compound of the invention and a pharmaceutically acceptable carrier. In another embodiment, the invention provides methods for treating hepatitis C viral infection comprising administering to a subject in need of such treatment an effective amount of a compound of the invention in combination 20 with another anti-viral agent. The term "anti-viral agent" as used herein denotes a compound which interferes with any stage of the viral life cycle to slow or prevent HCV reproduction. Representative anti-viral agents include, without limitation, NS3 protease inhibitors, INTRON-A, (interferon alfa-2b available from Schering Corporation, Kenilworth, N.J.), PEG-INTRON (peginteferon 25 alfa-2b, available from Schering Corporation, Kenilworth, N.J.), ROFERON-A 31 WO 2008/086161 PCT/US2008/050208 (recombinant interferon alfa-2a available Hoffmann-La Roche, Nutley, N.J.), PEGASYS (peginterferon alfa-2a available Hoffmann-La Roche, Nutley, N.J.), INFERGEN A (Schering Plough, inteferon-alpha 2B+Ribavirin), WELLFERON (interferon alpha-ni), nucleoside analogues, IRES inhbitors, NS5b inhibitors, El 5 inhibitors, E2 inhibitors, IMPDH inhibitors, NS5 polymerase inhibitors and/ior NTPase/helicase inhibitors. In certain embodiments, the methods of treating HCV infection include administering to a subject in need of such treatment an effective amount of a compound of the invention in combination with another NS3 protease inhibitor. Examples of other NS3 protease inhibitors which can be 10 administered in combination with compounds of the present invention include, without limitation, VX950 and BILN2061 (Lin C, Lin K, Luong Y, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD, "In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors VX950 and BILN2061", J. Biol. Chem., 2004, 15 279, 17508-514). Still other antiviral agents that may be used in conjunction with inventive compounds for the treatment of HCV infection include, but are not limited to, ribavirin (1-beta-D-ribofuranosyl-1H-1,2,- 4-triazole-3-carboxamide, available from ICN Pharmaceuticals, Inc., Costa Mesa, Calif.; described in the Merck 20 Index, entry 8365, Twelfth Edition); REBETROL.RTM. (Schering Corporation, Kenilworth, N.J.), COPEGASUS.RTM. (Hoffmann-La Roche, Nutley, N.J.); BEREFOR.RTM. (interferon alfa 2 available from Boehringer Ingelheim Pharmaceutical, Inc., Ridgefield, Conn.); SUMIFERON.RTM. (a purified blend of natural alpha interferons such as Sumiferon available from Sumitomo, Japan); 25 ALFERON.RTM. (a mixture of natural alpha interferons made by Interferon Sciences, and available from Purdue Frederick Co., CT); .alpha.-interferon; natural alpha interferon 2a; natural alpha interferon 2b; pegylated alpha interferon 2a or 2b; consensus alpha interferon (Amgen, Inc., Newbury Park, Calif.); VIRAFERON.RTM.; INFERGEN.RTM.; REBETRON.RTM. (Schering 30 Plough, Inteferon-alpha 2B+Ribavirin); pegylated interferon alpha (Reddy, K. R. et al. "Efficacy and Safety of Pegylated (40-kd) Interferon alpha-2a Compared with Interferon alpha-2a in Noncirrhotic Patients with Chronic Hepatitis C (Hepatology, 33, pp. 433-438 (2001); consensus interferon (Kao, J. H., et al.," Efficacy of Consensus Interferon in the Treatment of Chronic Hepatitis" J. 32 WO 2008/086161 PCT/US2008/050208 Gastroenterol. Hepatol. 15, pp. 1418-1423 (2000); lymphoblastoid or "natural" interferon; interferon tau (Clayette, P. et al., "IFN-tau, A New Interferon Type I with Antiretroviral activity" Pathol. Biol. (Paris) 47, pp. 553-559 (1999); interleukin 2 (Davis, G. L. et al., "Future Options for the Management of 5 Hepatitis C." Seminars in Liver Disease, 19, pp. 103-112 (1999); Interleukin 6 (Davis et al. "Future Options for the Management of Hepatitis C." Seminars in Liver Disease 19, pp. 103-112 (1999); interleukin 12 (Davis, G. L. et al., "Future Options for the Management of Hepatitis C." Seminars in Liver Disease, 19, pp. 103-112 (1999); and compounds that enhance the development of type 1 helper 10 T cell response (Davis et al., "Future Options for the Management of hepatitis C." Seminars in Liver Disease, 19, pp. 103-112 (1999)). Also included are compounds that stimulate the synthesis of interferon in cells (Tazulakhova, E. B. et al., "Russian Experience in Screening, analysis, and Clinical Application of Novel Interferon Inducers" J. Interferon Cytokine Res., 21 pp. 65-73) including, 15 but are not limited to, double stranded RNA, alone or in combination with tobramycin, and Imiquimod (3M Pharmaceuticals; Sauder, D. N. "Immunomodulatory and Pharmacologic Properties of Imiquimod" J. Am. Acad. Dermatol., 43 pp. S6-11 (2000) In another embodiment, the invention provides a method for treating 20 hepatitis C viral infection, comprising administering to a subject in need of such treatment an effective amount of a compound of the invention in combination with an anti-proliferative agent. The term "anti-proliferative agent" as used herein denotes a compound which inhibits cellular proliferation. Cellular proliferation can occur, for example without limitation, during carcinogenesis, 25 metastasis, and immune responses. Representative anti-proliferative agents include, without limitation, 5-fluorouracil, daunomycin, mitomycin, bleomycin, dexamethasone, methotrexate, cytarabine, mercaptopurine. In another embodiment, the invention provides a method for treating hepatitis C viral infection, comprising administering to a subject in need of such 30 treatment an effective amount of a compound of the invention in combination with an immune modulator. The term "immune modulator" as used herein denotes a compound or composition comprising a plurality of compounds which changes any aspect of the functioning of the immune system. In this context, immune modulator includes without limitation anti-inflammatory agents and 33 WO 2008/086161 PCT/US2008/050208 immune suppressants. Representative immune modulator include without limitation steroids, non-steroidal anti-inflammatories, COX2 inhibitors, anti TNF compounds, anti-IL-1 compounds, methotrexate, leflunomide, cyclosporin, FK506 and combinations of any two or more thereof. Representative steroids in 5 this context include without limitation prednisone, prednisolone, and dexamethasone. Representative non-steroidal anti-inflammatory agents in this context include without limitation ibuprofen, naproxen, diclofenac, and indomethacin. Representative COX2 inhibitors in this context include without limitation rofecoxib and celecoxib. Representative Anti-TNF compounds in this 10 context include without limitation enbrel, infliximab, and adalumimab. Representative anti-IL-I compounds in this context include without limitation anakinra. Representative immune suppressants include without limitation cyclosporin and FK506. Compounds of the invention include mixtures of stereoisomers such as 15 mixtures of diastereomers and/or enantiomers. In some embodiments, the compound, e.g. of Formula X, is 90 weight percent (wt %) or greater of a single diastereomer of enantiomer. In other embodiments, the compound is 92, 94, 96, 98 or even 99 wt % or more of a single diastereomer or single enantiomer. A variety of uses of the invention compounds are possible along the lines 20 of the various methods of treating a subject as described above. Exemplary uses of the invention methods include, without limitation, use of a compound of the invention in a medicament or for the manufacture of a medicament for treating a condition that is regulated or normalized via inhibition of the HCV NS3 serine protease. 25 Biochemical methods Fluorescence resonance energy transfer (FRET; see e.g., Heim et al., (1996) Curr. Biol. 6:178-182; Mitra et al., (1996) Gene 173:13-17; and Selvin et al., (1995) Meth. Enzymol. 246:300-345) is an exquisitely sensitive method for detecting energy transfer between two fluorophoric probes. As known in the art, 30 such probes are given the designations "donor" and "acceptor" depending on the relative positions of the maxima in the absorption and emission spectra characterizing the probes. If the emssion spectrum of the acceptor overlaps the absorption spectrum of the donor, energy transfer can occur. Because of the known and highly non-linear relationship of energy transfer and distance 34 WO 2008/086161 PCT/US2008/050208 between fluorophores, approximated by an inverse sixth power dependence on distance, FRET measurements correlate with distance. For example, when the probes are in proximity, such as when the probes are attached to the N- and C termini of a peptide substrate, and the sample is illuminated in a 5 spectrofluorometer, resonance energy can be transferred from one excited probe to the other resulting in observable signal. Upon scission of the peptide linking the probes, the average distance between probes increases such that energy transfer between donor and accept probe is not observed. As a result, the degree of hydrolysis of the peptide substrate, and the level of activity of the protease 10 catalyzing hydrolysis of the peptide substrate, can be quantitated. Accordingly, using methods known in the arts of chemical and biochemical kinetics and equilibria, the effect of inhibitor on protease activity can be quantitated. Compositions and Combination Treatments 15 A. Compositions. Another aspect of the invention provides compositions of the compounds of the invention, alone or in combination with another NS3 protease inhibitor or another type of antiviral agent and/or another type of therapeutic agent. As set forth herein, compounds of the invention include stereoisomers, tautomers, 20 solvates, prodrugs, pharmaceutically acceptable salts and mixtures thereof. Compositions containing a compound of the invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice ofPharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, 25 suspensions or topical applications. Typical compositions include a compound of the invention which inhibits the enzymatic activity of the HCV NS3 protease, and a pharmaceutically acceptable excipient which may be a carrier or a diluent. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or 30 enclosed within a carrier which may be in the form of an ampoule, capsule, sachet, paper, or other container. When the active compound is mixed with a carrier, or when the carrier serves as a diluent, it may be solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid carrier, 35 WO 2008/086161 PCT/US2008/050208 for example contained in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, 5 pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl 10 distearate, alone or mixed with a wax. The formulations can be mixed with auxiliary agents which do not deleteriously react with the active compounds. Such additives can include wetting agents, emulsifying and suspending agents, salt for influencing osmotic pressure, buffers and/or coloring substances preserving agents, sweetening 15 agents or flavoring agents. The compositions can also be sterilized if desired. The route of administration may be any route which effectively transports the active compound of the invention which inhibits the enzymatic activity of the HCV NS3 protease to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or 20 parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred. If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in 25 the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution. Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent 30 and a suspending agent Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or 36 WO 2008/086161 PCT/US2008/050208 suspending agents. Preferably, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides. For injection, the formulation may also be a powder suitable for reconstitution with an appropriate solution as described above. Examples of 5 these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For injection, the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The compounds may be formulated for parenteral administration by injection such as 10 by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers. The formulations of the invention may be designed to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. Thus, the formulations may also be 15 formulated for controlled release or for slow release. Compositions contemplated by the present invention may comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the formulations may be compressed into pellets or 20 cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers, e.g., polylactide-polyglycolide. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). 25 For nasal administration, the preparation may contain a compound of the invention which inhibits the enzymatic activity of the HCV NS3 protease, dissolved or suspended in a liquid carrier, preferably an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g., propylene glycol, surfactants, absorption enhancers such as lecithin 30 (phosphatidylcholine) or cyclodextrin, or preservatives such as parabens. For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil. 37 WO 2008/086161 PCT/US2008/050208 Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed. 5 A typical tablet that may be prepared by conventional tabletting techniques may contain: Core: Active compound (as free compound or salt thereof) 250 mg 10 Colloidal silicon dioxide (Aerosil)@ 1.5 mg Cellulose, microcryst. (Avicel)@ 70 mg Modified cellulose gum (Ac-Di-Sol)@ 7.5 mg Magnesium stearate Ad. Coating: 15 HPMC approx. 9 mg *Mywacett 9-40 T approx. 0.9 mg *Acylated monoglyceride used as plasticizer for film coating. A typical capsule for oral administration contains compounds of the 20 invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule. A typical injectable preparation is produced by aseptically placing 250 mg of compounds of the invention into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of sterile 25 physiological saline, to produce an injectable preparation. The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g., HCV infection. Such mammals include also animals, both domestic animals, e.g. 30 household pets, farm animals, and non-domestic animals such as wildlife. The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 5000 mg, preferably from about 1 to about 2000 mg, and more preferably between about 2 and about 2000 mg per day may be used. A typical dosage is 38 WO 2008/086161 PCT/US2008/050208 about 10 mg to about 1000 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the activity of the compound, mode of administration, on the therapy 5 desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge. HCV NS3 protease inhibitor activity of the compounds of the invention may be determined by use of an in vitro assay system which measures the potentiation of inhibition of the HCV NS3 protease. 10 Inhibition constants (i.e., Ki or IC 50 values as known in the art) for the HCV NS3 protease inhibitors of the invention may be determined by the method described in the Examples. Generally, the compounds of the invention are dispensed in unit dosage form comprising from about 0.05 mg to about 1000 mg of active ingredient 15 together with a pharmaceutically acceptable carrier per unit dosage. Usually, dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 125 tg to about 1250 mg, preferably from about 250 tg to about 500 mg, and more preferably from about 2.5 mg to about 250 mg, of the compounds admixed with a pharmaceutically acceptable carrier 20 or diluent. The invention also encompasses prodrugs of a compound of the invention which on administration undergo chemical conversion by metabolic or other physiological processes before becoming active pharmacological substances. Conversion by metabolic or other physiological processes includes 25 without limitation enzymatic (e.g, specific enzymatically catalyzed) and non enzymatic (e.g., general or specific acid or base induced) chemical transformation of the prodrug into the active pharmacological substance. In general, such prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into a compound of the invention. 30 Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design ofProdrugs, ed. H. Bundgaard, Elsevier, 1985. In another aspect, there are provided methods of making a composition of a compound described herein comprising formulating a compound of the 39 WO 2008/086161 PCT/US2008/050208 invention with a pharmaceutically acceptable carrier or diluent. In some embodiments, the pharmaceutically acceptable carrier or diluent is suitable for oral administration. In some such embodiments, the methods may further comprise the step of formulating the composition into a tablet or capsule. In 5 other embodiments, the pharmaceutically acceptable carrier or diluent is suitable for parenteral administration. In some such embodiments, the methods further comprise the step of lyophilizing the composition to form a lyophilized preparation. 10 B. Combinations. The compounds of the invention may be used in combination with i) one or more other NS3 protease inhibitors and/or ii) one or more other types of antiviral agents (employed to treat viral infection and related diseases) and/or one or more other types of therapeutic agents which may be administered orally 15 in the same dosage form, in a separate oral dosage form (e.g., sequentially or non-sequentially) or by injection together or separately (e.g., sequentially or non sequentially). Accordingly, in another aspect the invention provides combinations, comprising: 20 a) a compound of the invention as described herein; and b) one or more compounds comprising: i) other compounds of the present invention ii) anti-viral agents including, but not limited to, other NS3 protease inhibitors 25 iii) anti-proliferative agents iv) immune modulators. Combinations of the invention include mixtures of compounds from (a) and (b) in a single formulation and compounds from (a) and (b) as separate formulations. Some combinations of the invention may be packaged as separate 30 formulations in a kit. In some embodiments, two or more compounds from (b) are formulated together while a compound of the invention is formulated separately. Combinations of the invention can further comprise a pharmaceutically acceptable carrier. In some embodiments, the compound of the invention is 90 40 WO 2008/086161 PCT/US2008/050208 wt % or more of a single diastereomer or single enantiomer. Alternatively, the compound of the invention can be 91, 92, 93, 94, 95, 96, 97, 98, or 99 wt % or more of a single diastereomer or single enantiomer. The dosages and formulations for the other antiviral agent to be employed, 5 where applicable, will be as set out in the latest edition of the Physicians' Desk Reference. In carrying out the methods of the invention, a composition may be employed containing the compounds of the invention, with or without another antiviral agent and/or other type therapeutic agent, in association with a 10 pharmaceutical vehicle or diluent. The composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration. The compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, 15 capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations. The dose for adult humans is preferably between 10 and 1,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day. 20 Methods of Synthesis Embodiments of compounds of formula X of the invention can be prepared according to embodiments of synthetic methods of the invention. For example, compound Y can be prepared by an olefin metathesis reaction using a transition metal catalyst, as shown in the following scheme: F F O N O O Grubb's catalyst o 0 o SN HN Boc, N H = 0 H Boc' 19 20 25 41 WO 2008/086161 PCT/US2008/050208 using Grubb's catalyst or the like in an inert solvent such as dichloromethane. The solution can be deoxygenated before carrying out the metathesis reaction. Accordingly, a general method of synthesis of embodiments of compounds of the invention provides a method of preparing a compound of 5 formula X, comprising contacting a compound of formula XII:
R
2 a R 2 O PG 0 N R) H P
R
1 a N TK- -W-D M m n XII with a transition metal catalyst in an amount, at a temperature, and for a duration effective to form the compound of formula XIII
R
2 a R 2 0 O PG Z- y-X N R 6 H P
R
1 a N R1 0 T-K V W-D M 10 m n XIII wherein PG is a carboxyl protecting group, then, converting PG to NRa R to provide a compound of formula X of claim 1 wherein L is C 2
H
2 . For example, the transition metal catalyst can be Grubb's catalyst, 15 benzylidene-bis(tricyclohexylphosphine)dichlororuthenium. 42 WO 2008/086161 PCT/US2008/050208 EXAMPLES The following abbreviations are used throughout this document. BOP Benzotriazol-l-yl-oxy-tris 5 (dimethylamino)phosphonium hexa-fluorophosphate CDI Carbonyl diimidazole DBU Diazabicycloundecane DCM Dichioromethane 10 DIEA, 'Pr 2 EtN NN-Diisoproylethylamine DMAP 4-(NN-dimethylamino)pyridine DMF NN-Dimethylformamide DMSO Dimethylsulfoxide EDC 1-Ethyl-3-[3-dimethylaminopropylcarbodiimide 15 hydrochloride EtOAc Ethyl acetate HATU 0-(7-Azabenzotriazole- 1 -yl)-N, N,N'N' tetramethyluronium hexafluorophosphate HOAT Hydroxyazabenztriazole 20 HOBT Hydroxybenzotriazole MS Mass spectroscopy MeOH Methanol NaH Sodium hydride NMM N-Methylmorpholine 25 THF Tetrahydrofuran The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an 30 illustration only and not to limit the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or 43 WO 2008/086161 PCT/US2008/050208 methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims. Compounds of formula X, wherein common terms are as defined above, may be conveniently prepared by the process outlined in Scheme 1 below. 5 Scheme 1 MeO
H
2 N o z Z HX Y LOH LH xO OMe OH |N| N Bo O BocHN N c N SIl IV 10 OH T'K W'' T' VAl 0 Z Z, HCI O X - 0 _ _ _ _ N (7VI 0 HN H HN TsK 'VWI. 0 0 0 O \ VII V z Y X HO Grubb's catalyst 0-0O O~ LiOH O O __.___NH__ O N NH ) p 0 1 O /w K'T 15 VilI Ix 44 WO 2008/086161 PCT/US2008/050208 Z, Yb Ra Rb X N 0 O N NH p T K-V'W ,KV X Generally, the processes for preparing the compounds of formula X where X, Y, Z, W, V, K, and 5 T are as defined above comprise the steps of: a) hydrolyzing a compound of formula I with lithium hydroxide; b) coupling a compound of formula II with an amino acid of formula III; c) removing a nitrogen protecting group from a compound of formula IV; d) coupling a compound of formula V with an amino acid of formula VI to 10 produce a compound of formula VII; e) forming a macrocycle by reaction a compound of formula VII with a metathesis catalyst such as Grubb's catalyst; f) hydrolyzing a compound of formula VIII with lithium hydroxide to provide a compound of formula IX; and, 15 g) forming an amide of the compound of formula IX to provide the inventive compound of formula X. A particular example of a compound 6 of formula VI was prepared as outlined in Scheme 2. 45 WO 2008/086161 PCT/US2008/050208 Scheme 2 NIHAc OH NalO4 / COOEt OH H Ac 2 O 1 3 NHAc NaOH NHAc EtOOC COOEt HOOC COOEt 2 (COD)Rh((SS) , NIHAc Et-DUPHOS))OTf NHAc COOEt COOEt
H
2 3 4 BooNHo (Boc) 2 0 NAc LiOH OOH COGEt CO 5 6 Synthesis of compound 1: NaIO 4 OH OH H 5 To a magnetically stirred emulsion of commercially available 7-octene 1,2-diol (5 g, 34.7 mmol) and H 2 0 (20 mL), an aqueous solution of NaIO 4 (8.14 g, 38.2 mmol, in 47.5 mL H 2 0) was added over a period of 45 min (slight exotherm observed). The resulting mixture was stirred at room temperature for 10 an additional 1.5 hour (completion of reaction confirmed by TLC). The mixture was then decanted in a separatory funnel and the layers were separated. The organic fraction was dried with sodium sulfate and filtered over a cotton plug (in a Pasteur pipette) to give compound 1 (2.99 g ). The aqueous solution was saturated with NaCl, extracted with DCM, dried with anhydrous MgSO4, and 46 WO 2008/086161 PCT/US2008/050208 concentrated under reduced pressure (without heating, heptenal b.p. 153 C) to obtain an additional amount of compound 1 (0.855 g). The two fractions were combined to afford the title compound 1 (3.85 g) as a colorless oil. Synthesis of compound 2: NHAc NaOH NHAc EtOOC COOEt HOOC COOEt 5 2 To a stirred solution of diethyl 2-acetamidomalonate (10 g, 46 mmol) in dioxane (60 mL) was added aqueous sodium hydroxide (1 M, 46.5mL) dropwise over 2 h. The resulting mixture was stirred at room temperature for 15 h, then dioxane was evaporated under reduced pressure, the aqueous solution was 10 washed with three portions of 30 mL of EtOAc and filtered. The filtrate was cooled down to 0 'C and acidified to pH=1 with concentrated HCl (5 mL). After the appearance of a few crystals, the mixture was sonicated and an abundant precipitate appeared. Filtration and drying under reduced pressure afforded the titled compound 2 (7.084 g) as a white solid. 15 Synthesis of compound 3: 2 )-UNHAc 7 0 ~COOEt H Ac 2 O 1 3 To solid ethyl 2-acetamidomalonate 2 (3.78 g, 20 mmol) was added 1 (2.24 g, 20 mmol.) in solution in pyridine (16 mL). The resulting solution was cooled in a -15 'C bath (KC1 / ice) and acetic anhydride (6 mL) was added over 20 12 min. The resulting orange solution was stirred for 3 h at room temperature and another portion of ethyl 2-acetamidomalonate 2 (1.14 g) was added. The resulting mixture was stirred at room temperature for an extra 15 h. Ice (25 g) was then added and the solution was stirred for 1.5 h, then the mixture was diluted with 100 mL of water and extracted with two portions (75 mL) of ether. 25 The etheral solution was washed with IN HCl (30 mL), sat. NaHCO 3 (30 mL) and brine (30 mL), dried with Na 2
SO
4 , concentrated to afford an orange oil (3.71 g) and purified by flash chromatography (EtOAc : hexane = 2: 3) to give 3 (2.33 g) as a pale yellow oil. 47 WO 2008/086161 PCT/US2008/050208 Synthesis of compound 4: (COD)Rh((S,S) NHAc Et-DUPHOS))OTf NHAc COOEt COOEt
H
2 3 4 To a degassed (argon bubbling for 30 min.) solution of Z-ethyl 2 acetamido-2,8- nonadienoate 3 (2.73 g, 11.34 mmol) in dry ethanol (20 mL) was 5 added (SS)-Me-DUPHOS Rh(COD)OTf (9.6 mg, S/C = 857). The mixture was put under 45 psi of hydrogen (after 4 vacuum-H 2 cycles) and stirred for18 h. The resulting mixture was concentrated under reduced pressure to afford the desired compound 4 (2.74 g), which was used in the subsequent step without purification. 10 Synthesis of compound 5: Boc~ HAc (Boc) 2 0 Ac COOEt : COOEt 4 5 To a solution of crude (S)-ethyl 2-acetamido-8-nonenoate 4 (1.38 g, 5.71 mmol) in THF (16 mL) were added Boc 2 0 (2.49 g, 2 eq.) and DMAP (139.5 mg, 0.2 eq.), the resultant reaction mixture was heated to reflux for 3.5 h. The 15 reaction mixture was concentrated, diluted with DCM (50 mL), washed with HC (1 N) (20 mL), brine (15 mL), then saturated aqueous NaHCO 3 (20 mL), dried with MgSO4. The resulting solution was concentrated under reduced pressure. This compound was used to the next step without further purification. 20 Synthesis of compound 6: Boc~ Ho N~c LiOH COOEt L COOH 5 6 The crude product of 5 was then diluted with THF (12 mL) and water (7.5 mL), LiOH.H 2 0 (0.48 g, 2 eq.) was added and the resulting mixture was stirred at rt for 18 h (completion of the hydrolysis was confirmed by TLC). The 48 WO 2008/086161 PCT/US2008/050208 reaction mixture was concentrated under reduced pressure, then diluted with DCM (50 mL), washed with HCl (1 N) (15 mL), dried with anhydrous Na 2
SO
4 and concentrated under reduced pressure. This crude product was purified by flash column chromatography (EtOAc : hexane = 0:100 to 100:0). The titled 5 compound 6 was obtained as a pale yellow oil (697 mg). LC-MS (ESI, positive): 272 [M+H]+. A particular example of a compound 11 of formula III was prepared as outlined in Scheme 3. Scheme 3 0 )Br - Br H 2 N CO 2 Me
H
2 N CO 2 Me. HCI -N-CO 2 Me ________H___ 2) H+, OH 8 Boc, TsOH (Boc)20 BocHN Alcalase 2.4L HN CO 2 Me H+ H 2 N CO 2 Me (Boc)0 HN CO 2 Me Na 2
HPO
4 H KCilacetone/water H H pH=8.1-8.2 3days 10 10 10 Synthesis of compound 7 0
H
2 N C0 2 Me. HCI NGC0 2 Me 15 Glycine methyl ester hydrochloride (37.8 g, 300 mmol) was suspended in
CH
2 Cl 2 (300 mL) in a 1 L of flask. The benzaldehyde (31.8 g, 330 mmol) was added to the reaction mixture. After adding of anhydrous MgSO 4 (21.6 g, 180 mmol), the resultant suspension was cooled in ice to an internal temperature 20 lower than 5 C, and triethylamine (45.6 g, 450 mmol) was added dropwise over 10 min with vigorous stirring. The mixture was then stirred 24 h at room 49 WO 2008/086161 PCT/US2008/050208 temperature. The mixture was filtered, and the filtrate was evaporated under reduced pressure. The residue was dried to a constant weight under high vacuum to give the desired crude imine as an yellow oil that was used directly in the next step. 52 g of the compound 7 was obtained. 5 Synthesis of compound 9 Boc, 'N 1 )Br -\ Br H 2 N CO 2 Me (Boc) 2 0 HN CO 2 Me N CO 2 Me _____ H H 2) H+, OH 7 8 9 t-BuOLi (45.7 g, 571 mmol) was suspended in toluene (400 mL) at room temperature. A freshly prepared mixture of 7 (50 g, 286 mmol) and 1,4-dibromo butene (57 g, 272 mmol) in toluene (200 mL) was added dropwise over 30 min 10 to the stirred suspension of the base. After stirring for 60 min at rt, the reaction was quenched by addition of water (100 mL), the organic phase was extracted with TBME (500 mL). The organic phase was mixed with iN HC1 (200 mL) and stirred for 2 h at room temperature to hydrolysis of the intermediate imine. The organic phase was separated and extracted with water (2*200 mL). The 15 combined aqueous phase were mixed with NaCl (250 g) and TBME (300 mL), and ION NaOH (30 mL) was added dropwise to bring the pH to 12-13. The organic phase was separated and the aqueous phase extracted with additional TBME (3*200 mL). The combined organic extracts containing compound 8 were mixed with Boc 2 0 (25 g, 115 mmol), and the solution stirred overnight at 20 room temperature. The mixture was then heated to 60 C for 2 h. The cooled solution was then dried over Na 2
SO
4 , and concentrated under reduced pressure. The residue was purified by flash column (P:E = 25:1 to 15:1) to give 33 g of compound 9. LC-MS (ESI, positive): 242 [M+H]*. Synthesis of compound 10 Boc, Alcalase 2.4L BocHN HN CO 2 Me Na 2
HPO
4 H CO 2 Me H KCI/acetone/water H pH=8.1-8.2 days 25 10 50 WO 2008/086161 PCT/US2008/050208 A reactor was charged with Na 2
HPO
4 (7.6 g, 55 mmol), water (220 mL) and Alcalase 2.4L (11 mL). The pH was adjusted to 8.15 by additional Na 2
HPO
4 (188 mg, 1.3 mmol). Racemic 9 (7.3 g, 30 mmol) in acetone (15 mL) was added and the mixture was stirred at 40 C while maintaining the pH at 8.15 by 5 periodic addition of IN NaOH (20 mL). Enantiomeric purity of the remaining ester was monitored by HPLC analysis. Heating was discontinued after 70 h and TBME (3*100 mL) was added to extract the resolved ester. The extract was washed with water (2*50 mL), concentrated under vacuum and used directly in the next step. 3.77 g of compound 10 was produced. LC-MS (ESI, positive): 242 10 [M+H]*. Synthesis of compound 11 Boc, TsOH HN CO 2 Me H+ H 2 N CO 2 Me H H 11 12 The 11 (3.77 g, 16 mmol) was added into a reactor and most of the solvent removed in vacuum. MIBK (4 mL) was added and warmed to 40 C. P 15 TsOH (4.46 g, 23 mmol) in a mixture of MeOH (0.9 mL) and MIBK (4 mL) was added and the mixture stirred for 2 h. The mixture was then cooled to 3-8 0 C and stirred for an additional 2 h. The product was isolated by filtration, washed with MIBK (30 mL) to give 4.1 g of compound 12. LC-MS (ESI, positive): 142 [M+H]*. 20 51 WO 2008/086161 PCT/US2008/050208 A particular example of a compound 21 of formula IX was prepared as outlined in Scheme 4. Scheme 4 O NH NH F 0 F 0 F 13 14 HQ 1. CO 2 Me O O Boc N 'O.- OH BTC, DMAP F N Boc 2. LiOH 15 5 Synthesis of compound 13 0 0
NH
3 NH 1 40 H 2 0 F 0 13 In a 50 ml flask was placed 3-Fluorophthalic anhydride (1.0 g, 6 mmol) and aqueous NH 3 (1.6 g, 24 mmol). The mixture was heated to 280 C within 30 10 minutes and then the flask was cooled to room temperature. 0.93 g of compound 13 were isolated as a yellow solid. LC-MS (ESI, positive): 166 [M+H]*. Synthesis of compound 14 0 N BH, I NH I NH THF F 0 F 13 14 15 To compound 13 (4.0 g, 24.2 mmol) in a round bottom flask was added 1 M BH 3 in THF solution (97 mL, 97 mmol) dropwise at room temperature. The resulting solution was warmed to reflux for 18 hours. Then the reaction mixture was cooled to 0 'C and methanol (3.1 g, 97 mmol) was added dropwise. The resulting mixture was warmed up to room temperature and then 6 M HCl was 20 added dropwise to adjust the reaction pH to 3, followed by refluxed for 1 hour. 52 WO 2008/086161 PCT/US2008/050208 After the reaction was completed, the solvents were removed under reduced pressure to give an brown oil. The residue was washed with Et 2 0 (2x50 ml) and
CH
2 Cl 2 (2x50 mL). The aqueous phase was adjusted to pH 11 with NaOH. Then the aqueous layer was extracted with ether (4x50 mL), dried over Na 2
SO
4 , and 5 filtered. Solvents were removed under reduced pressure to give a dark red residue. The pure compound was purified by distillation (2 mmHg, 45 C) to give compound 14 (1.2 g). Synthesis of compound 15 HQ N CO 2 Me q NH Boc N 2 ,N-P F BTC, DMAP, CH 2 Cl 2 I Boc 14 15 10 A solution of 14 (4.113 g, 16.8 mmol) and DMAP (3.072 g, 25 mmol) in dichloromethane (17 mL) was added directly to a solution of BTC (1.994 g, 6.7 mmol) in dichloromethane (17 mL) at 0 C. After the addition was finished, the reaction mixture was stirred at room temperature for 3 hrs. Then the mixture was cooled to 0 'C and a solution of DMAP (3.072 g, 25 mmol) in dichloromethane 15 (17 mL) and a solution of Boc trans-hydroxyproline methylester (2.3 g, 16.8 mmol) in dichloromethane (17 mL) were added sequentially. The reaction mixture was stirred at room temperature overnight. Dichloromethane (100 mL) was added to the reaction mixture and the organic layer was washed with IN HCl (50 mL), saturated aqueous NaHCO 3 (50 mL) and brine (50 mL). It was 20 dried over anhydrous Na 2
SO
4 and filtered. After removal of solvents under reduced pressure, the residue was purified by silica gel column chromatography (elution solvent system PE:EA = 2:1 to 1:3) to get the compound 15 (3.8 g). LC MS (ESI, positive): 409 [M+H]*. 53 WO 2008/086161 PCT/US2008/050208 Synthesis of compound 16 F F )=0 UOH O OMe OH Boc 0 Boc 15 16 Compound 15 (1.7 g, 4.1 mmol) was dissolved in THF (10 mL), aqueous LiOH (0.5 N, 16 ml) was added and the resulting solution was stirred for 3 h at 5 room temperature. Evaporated most of THF and adjusted the value of pH to 3 with IN HCl (10 mL) and extracted with DCM (60 mL), combined the organic phase, dried over anhydrous Na 2
SO
4 , filtrated the Na 2
SO
4 , and evaporated the solvent, 1.6 g of compound 16 was produced. LC-MS (ESI, positive): 395 [M+H]*. 10 Synthesis of compound 17 F MeO
H
2 N o N F N H N O H/ O0 OH 2 oc HN Boc o 0 16 17 The solution of 16 (1.6 g, 4 mmol) in DCM (10 mL) was added HATU (2.2 g, 6 mmol). 2 (1.9 g, 6 mmol) in DCM (5 mL) was added DIPEA (5 g, 40 15 mmol), the resulting solution was added into the solution of 16, the reaction mixture was concentrated to dryness, the residue, diluted with EA (50 mL), wash with saturated NaHCO 3 (20 mL) and brine (20 mL) in sequence, dried over anhydrous Na 2
SO
4 , filtered and concentrated under vacuum. The residue was purified by column chromatography to provide 1.7 g of 17. LC-MS (ESI, 20 positive): 518 [M+H]+. 54 WO 2008/086161 PCT/US2008/050208 Synthesis of compound 18 F F N N HCI Boc HN H HN 0 00 17 18 2 ml of TFA was added to a solution of 17 (450 mg, 0.87 mmol) in 5 DCM (5 mL) and the resulting mixture was stirred at rt for 2h. After the removal of the solvent and TFA under reduced pressure, the residue containing compound 18 was used directly to the next step. LC-MS (ESI, positive): 418 [M+H]*. Synthesis of compound 19 F F q N O N0 09 HATU, 6 0/ N O N H HN Boc HN HN 0 0 0 18 19 10 The resulting amine intermediate 18 was then dissolved in a mixture of DCM (5 mL) and DIPEA (561mg, 5eq) (solution A). Separately, a mixture of 6 (330 mg, 1.2 mmol), HATU (496 mg, 1.5 eq.) and DIPEA (561 mg, 5eq) in DCM (5 mL) were allowed to react for 10-20 min. To the resulting mixture was 15 added to solution A dropwise and the resulting solution was left to stir at rt for 3 h. The reaction solution was then concentrated under reduced pressure, diluted with EtOAc (50 mL), washed with aqueous HCl (0.5 N) (20 mL), water (20 mL) and NaHCO 3 (sat.) (20 mL), dried with MgSO 4 , and concentrated under reduced pressure. The resulting yellow oil was purified by flash column chromatography 55 WO 2008/086161 PCT/US2008/050208 (EtOAc: hexane = 4:3) to afford 18 (500 mg) as a white foam. LC-MS (ESI, positive): 671 [M+H]*. Synthesis of compound 20 F F N O Grubb's catalyst Q o_ Boc, 0N NH HN0 - O Boc Boa' 19 20 5 A solution of 19 (500 mg, 0.75 mmol) in dry DCM (20 ml) was deoxygenated (bubbling Ar for 2 h). Grubb's catalyst (22 mg, 5 mol %) was then added as a solid and the reaction was refluxed under argon. After 24 h, the red orange solution was evaporated to an amorphous residue which was then 10 purified by flash column chromatography (EtOAc 10% / DCM, then EtOAc100%). The macrocyclic product 20 was isolated as a brown solid (200 mg). LC-MS (ESI, positive): 643 [M+H]*. Synthesis of compound 21 F 0 OiOH HO NH NHoN0 Bo N Boc-N/ HN" H Boo' 15 20 21 0.46 ml aqueous solution of LiOH (IN solution, 2eq) was added to a solution of 20 (200 mg, 0.23 mmol) in 0.46 ml THF. The mixture was stirred at 30 0 C for 2 h (completion of reaction confirmed by TLC). The reaction mixture was concentrated under reduced pressure, then diluted with DCM (50 mL), 20 washed with HCl (IN) (20 mL) under 0 C, dried over anhydrous Na 2
SO
4 and 56 WO 2008/086161 PCT/US2008/050208 concentrated under reduced pressure to afford a brown solid. This crude product was purified by column chromatography (EtOAc 100%, then methanol) to give compound 21 (100mg). LC-MS (ESI, positive): 629 [M+H]*. Synthesis of a compound of formula X F N Q 0 H NH N H O O N O 5 0 22 A solution of 21 (0.01 g, 0.016 mmol), HATU (0.007 g, 0.019 mmol), 10 and DIEA (11.11 [L, 0.0636 mmol) in dry DMF was stirred for 1h before the addition of a solution containing phenethylamine (0.003 g, 0.0239 mmol), DMAP (0.008 g, 0.0652 mmol), and DBU (9.8 tL, 0.0652 mmol) in dry DMF. The mixture was stirred at room temperature overnight. The solution was loaded onto a preparatory column (50-100% ACN) to obtain 4 mg of a solid compound 15 22, a compound of formula X. LC/MS 2.33min, 732.33(M+1; 100). 57 WO 2008/086161 PCT/US2008/050208 Table 1. Exemplary Structures of formula X EXAMPLES STRUCTURE (prophetic 2 F N H H NH N H 0 O YN 0 0 3 F N O H NH N H N O N 0 4 F N N O O0 H NH N H 0 O N 0 0 5 F CI N Q 0 H NH N H N O N O 0 58 WO 2008/086161 PCT/US2008/050208 6 F ci N 0, 0 H NH N H N 0 O N O O ,O 0 7 F N 0 0 H NH H N 06 O N 0 8 F FF N F 0 O ,O H NH N H N O0 O N o 0 9 F F qO / N H NH N H N 0 O NO 0 59 WO 2008/086161 PCT/US2008/050208 10 F F F N F H NH N H 0 O yN 0 0 11 F N ci QC C H NH N H 0 O yN 0 0 12 F F N IF Q 0 H NH N H N 0 ON O 0 60

Claims (9)

1. A compound of Formula X: z X Rla R2a Ra N ( W D0 NH \N--Rb M (CHR6) 0 5 L P 5 X and stereoisomers, solvates, tautomers, prodrugs, salts, pharmaceutically acceptable salts, and mixtures thereof, wherein: Ra and Rb at each occurrence are independently H, OR 3 , NR 4 R', alkyl, 10 alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; or, Ra and Rb, together with a nitrogen atom to which they are bound, form a 3-8 membered heterocyclic ring 15 which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered heterocyclic ring can contain 1-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(0)2, wherein the 3-8 membered heterocyclic ring can be fused with a substituted or unsubstituted, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any combination thereof; 20 R', Ria, R2 and R 2 a are independently H or alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, 61 WO 2008/086161 PCT/US2008/050208 heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; R 3 , R 4 and R 5 are independently H or alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, 5 cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; or R 4 and R , together with a nitrogen atom to which they are bound, form a 3-8 membered heterocyclic ring which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered heterocyclic ring can contain 10 1-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(0) 2 , wherein the 3-8 membered heterocyclic ring can be fused with a cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any combination thereof; D is CH 2 , CH or N; 15 when D is CH 2 , then W, V, K and T are absent; when D is CH, then W is C( R6 ) 2, 0, S, or NR 7 , and V, K, and T are as defined below; when D is N then W, V and K are bonds, the bonds taken together forming a single bond, T is as defined below, such that T is bonded directly to D; 20 wherein R 6 is independently at each occurrence hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; or wherein two R 6 groups together 25 with a carbon atom to which they are bond form a 3-8 membered cycloalkyl, which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered cycloalkyl can contain 1-3 heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(0) 2 , wherein the 3-8 membered cycloalkyl can be fused with a cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any 30 combination thereof; R 7 is independently at each occurrence hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can 62 WO 2008/086161 PCT/US2008/050208 be substituted with J, or aralkanoyl, heteroaralkanoyl, C(O)R 8 , SO 2 R 8 or carboxamido, wherein any aralkanoyl or heteroaralkanoyl is substituted with 0-3 J groups; R is alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, 5 cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any carbon atom can be substituted with J; m is 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; 10 pis 1,2,3,or4; M is 0, S, S(O), S(0)2, C( R6 ) 2 or N(R7; J is halogen, R', OR', CN, CF 3 , OCF 3 , 0, S, C(O), S(O), methylenedioxy, ethylenedioxy, (CH 2 )o- 2 N(R') 2 , (CH 2 ) 0 - 2 SR', (CH 2 ) 0 - 2 S(O)R', (CH 2 ) 0 - 2 S(O) 2 R', (CH2)o-2S(O)2N(R')2, 15 (CH 2 ) 0 - 2 SO 3 R', (CH 2 ) 0 - 2 C(O)R', (CH 2 ) 0 - 2 C(O)C(O)R', (CH 2 ) 0 - 2 C(O)CH 2 C(O)R', (CH 2 ) 0 - 2 C(S)R', (CH 2 ) 0 - 2 C(O)OR', (CH 2 )o-20C(O)R', (CH 2 ) 0 - 2 C(O)N(R') 2 , (CH 2 ) 0 - 2 0C(O)N(R') 2 , (CH 2 ) 0 - 2 C(S)N(R') 2 , (CH 2 )o- 2 NH-C(O)R', (CH 2 )o- 2 N(R')N(R')C(O)R', (CH 2 )o- 2 N(R')N(R')C(O)OR', (CH 2 ) 0 - 2 N(R')N(R')CON(R') 2 , (CH 2 ) 0 - 2 N(R')SO 2 R', 20 (CH 2 ) 0 - 2 N(R')SO 2 N(R') 2 , (CH 2 ) 0 - 2 N(R')C(O)OR', (CH 2 ) 0 - 2 N(R')C(O)R', (CH 2 )o 2 N(R')C(S)R', (CH 2 )o- 2 N(R')C(O)N(R') 2 , (CH 2 ) 0 - 2 N(R')C(S)N(R') 2 , (CH 2 ) 0 2 N(COR')COR', (CH 2 ) 0 - 2 N(OR')R', (CH 2 ) 0 - 2 C(=NH)N(R') 2 , (CH 2 ) 0 2 C(O)N(OR')R', or (CH 2 )o- 2 C(=NOR')R'; wherein, each R' is independently at each occurrence hydrogen, (C 1 -C 12 )-alkyl, 25 (C 2 -C 12 )-alkenyl, (C 2 -C 1 2 )-alkynyl, (C 3 -Cio)-cycloalkyl, (C 3 -Cio)-cycloalkenyl, [(C 3 -Cio)cycloalkyl or (C 3 -Cio)-cycloalkenyl]-[(CI-C 1 2 )-alkyl or (C 2 -C 1 2) alkenyl or (C 2 -C 1 2 )-alkynyl], (C 6 -Cio)-aryl, (C 6 -Cio)-aryl-[(C 1 -C 1 2 )-alkyl or (C 2 C 1 2 )-alkenyl or (C 2 -C 12 )-alkynyl], (C 3 -Cio)-heterocyclyl, (C 3 -Cio)-heterocyclyl [(CI-C 1 2 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl], (C 5 -Cio)-heteroaryl, or 30 (C 5 -Cio)-heteroaryl-[(C1-C 1 2 )-alkyl or (C 2 -C 1 2 )-alkenyl or (C 2 -C 12 )-alkynyl], wherein R' is substituted with 0-3 substituents selected independently from J; or, when two R' are bound to a nitrogen atom or to two adjacent nitrogen atoms, the two R' groups together with the nitrogen atom or atoms to which they are bound can form a 3- to 8-membered monocyclic heterocyclic ring, or an 8- to 63 WO 2008/086161 PCT/US2008/050208
20-membered, bicyclic or tricyclic, heterocyclic ring system, wherein any ring or ring system can further contain 1-3 additional heteroatoms selected from the group consisting of N, NR 7 , 0, S, S(O) and S(O) 2 , wherein each ring is substituted with 0-3 substituents selected independently from J; 5 wherein, in any bicyclic or tricyclic ring system, each ring is linearly fused, bridged, or spirocyclic, wherein each ring is either aromatic or nonaromatic, wherein each ring can be fused to a (C 6 -Cio)aryl, (C 5 -Cio) heteroaryl, (C 3 -Cio)cycloalkyl or (C 3 -Cio) heterocyclyl; L is 0, S, C 2 , C2H 2 or C2H4; 10 V is a bond, C( R1 0 ) 2 , C(O), S(O), or S(O)2; K is a bond, 0, S, C(O), S(O), S(O) 2 , S(O)(NR 7 ), or N(R 7 ); provided that when V and K are both bonds, they form together a single bond; R1 0 is independently at each occurrence hydrogen, alkyl, cycloalkyl, 15 cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or, two Rio groups together with a carbon atom to which they are bound form a 3-8 membered cycloalkyl, which can be unsubstituted or substituted with 1-3 J, wherein the 3-8 membered cycloalkyl can contain 1-3 heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(0)2, 20 wherein the 3-8 membered cycloalkyl can be fused with a cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring, or any combination thereof; T is R", alkyl-R", alkenyl-R", alkynyl-R", OR", N(R" )2, C(O) R", or C(=NOalkyl) R"; R 1 is independently at each occurrence hydrogen, alkyl, aryl, aralkyl, 25 alkoxy, amino, alkylamino, dialkylamino, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl, wherein any R" except hydrogen is substituted with 0-3 J groups, or a first R" and a second R" together with a nitrogen atom to which they are bound form a mono 30 or bicyclic ring system substituted with 0-3 J groups and can contain 1-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(O) 2 ; and when W is C( R 6 ) 2 , a bond, or absent; X is a bond, 0, S, CH( R 6 ) or N(R7; 64 WO 2008/086161 PCT/US2008/050208 Y is a bond, CH(R 6 ), C(O), C(O)C(O), S(O), S(0) 2 , or S(O)(NR 7 ); provided that when both X and Y are bonds, they together form a single bond; Z is: 5 a) hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, OR 9 , or N(R9)2, wherein any carbon atom is unsubstituted or is substituted with J, and wherein R 9 is independently at each occurrence hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], heterocyclyl, 10 heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, or heteroarylalkyl, or two R9 groups together with a nitrogen atom to which they are bound can form together with the nitrogen atom a 5-11 membered mono- or bicyclic heterocyclic ring system substituted with 0-3 J groups and further including 0-3 additional heteroatoms selected from the group consisting of 0, NR 7 , S, S(O), and S(O) 2 ; 15 or b) a substituted aryl or heteroaryl group; wherein any aryl or heteroaryl is substituted with 1-3 J groups; c) a group of the formula: R 18 N h ) R17 R 1 9 / R14 20 R 15 R 16 , R , R 4 , R", R1 8 and R1 9 are independently hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, 25 heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R1 2 and R" or R14 and R" or R' and R19, together with a carbon atom to which they are attached, form a C 3 - 6 cycloalkyl group; 65 WO 2008/086161 PCT/US2008/050208 R16 and R are independently hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl] [alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or 5 R1 6 and R 1 7 together with the atoms to which they are attached form a fused substituted or unsubstituted aryl or heteroaryl group; g is 0-1; and h is 0-2; or 10 d) a group of the formula: RNR13 N R 14 h R 20 R15I R 23 R 21 R 22 wherein g is 0-2; and h is 0-2; 15 R 2 , R", R1 4 , and R 5 are independently at each occurrence hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R' and R" or R' 4 and R", 20 together with a carbon atom to which they are attached, form a C 3 . 6 cycloalkyl group; R20, R , R2, R3 are independently H, F, Cl, Br, I, CN, CF 3 , OCF 3 , OR 24 , (CH 2 )qOR 24 , O(CH 2 )qOR24 , NR R26, (CH 2 )qNRR26 O(CH 2 )qNR 25 R 26 , SR 24 , (CH 2 )qSR 24 , O(CH 2 )qSR 24 , C(O)R 2 4 , (CH 2 )qC(O)R 24 , 25 O(CH 2 )qC(O)R 2 4 , C(O)OR24, (CH 2 )qC(O)OR 2 4 , O(CH 2 )qC(O)OR24 NR 2 7 C(O)R 24 , (CH 2 )qNR 27 C(O)R 24 , O(CH 2 )qNR C(O)R24, C(O)NR R26 (CH 2 )qC(O)NR R26, O(CH 2 )qC(O)NR2R6 , NR C(O)NR R26 66 WO 2008/086161 PCT/US2008/050208 (CH 2 )qNR 27 C(O)NR 2 5 R 26 , O(CH 2 )qNR C(O)NR R 26 , OC(O)NR R26 (CH 2 )qOC(O)NReR 26 , O(CH 2 )qOC(O)NRR 26 , N 27 C(O)OR 2 4 , (CH 2 )qNR 7 C(O)OR 24 , O(CH 2 )qNR C(O)OR24, NR SO 2 R24 (CH 2 )qNR 7 SO2R 24 , O(CH 2 )qNR 2 7 SO 2 R 24 , S0 2 NRR 26 , (CH 2 )qSO 2 NR R , or 5 O(CH2)qSO2N 526, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group, q is 1, 2, 3, 4, 5, or 6; and 10 each R 24 , R, R 26 , and R 7 is independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, arylalkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R25 and R 26 together with a nitrogen atom to which 15 they are attached form a 3-7 membered heterocyclic ring substituted with 0-3 J groups, that further comprises 0-3 additional heteroatoms selected from the groups consisting of 0, NR 7 , S, S(O), and S(O) 2 ; or e) a group of the formula ~< R 1 2 N R 13 RM N R23 R 21 20 R22 wherein g is 0-2; and h is 0-2; 12 1 1415 p21 2anR2 R ,R 13 , R 14 ,R R ,R andR 2 3 are as defined in (d); 25 67 WO 2008/086161 PCT/US2008/050208 or f) a group of the formula R 13 N R 23 R 22. 5 wherein g is 0-2; and h is 0-2; 12 13512012 R , R', R 14 , R , R20, R2 and R 3 are as defined in (d); and wherein a wavy line signifies a point of attachment; 10 and, when W is NR 7 , or S: X is 0, CH 2 , or NR 7 ; Y is C(R 6 ) 2 or absent; Z is a substituted alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, 15 cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, arylamino, heteroaryl, or heteroarylalkyl; wherein any alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, alkoxy, aryloxy, alkylthio, 20 arylthio, alkylamino, arylamino, heteroaryl, or heteroarylalkyl is substituted with 1-3 J groups, provided that K and V are both bonds, taken together forming a single bond such that T is bonded directly to W, T is not C(O)R 1 ; or X is 0; Y is C(O); 25 68 WO 2008/086161 PCT/US2008/050208 Z is aa) a group of the formula ( R 1 2 R13 NR R 14 h R 20 R15 I R23 R21 R22. 5 wherein g is 0-2; and h is 0-2; R, 12 R, R1 4 , and R 5 are independently at each occurrence hydrogen, fluorine, or a substituted or unsubstituted alkyl, cycloalkyl, 10 cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R' and R' 3 or R' 4 and R", together with a carbon atom to which they are attached, form a C 3 - 6 cycloalkyl group; 15 R2, R21, R 2 , R 3 are independently H, F, Cl, Br, I, CN, CF 3 , OCF 3 , OR 24 , (CH 2 )qOR 24 , O(CH2)qOR 24, NR R 26, (CH 2 )qNR R26 O(CH 2 )qNR 2 5 R 26 , SR 24 , (CH 2 )qSR 24 , O(CH 2 )qSR 2 4 , C(O)R 2 4 , (CH 2 )qC(O)R 24 , O(CH 2 )qC(O)R 2 4 , C(O)OR 2 4 , (CH 2 )qC(O)OR 24 , O(CH 2 )qC(O)OR 24 , NR C(O)R 24 , (CH 2 )qNR 27 C(O)R 24, O(CH 2 )qNR27C(O)R4, C(O)NR R26 20 (CH 2 )qC(O)NR R26, O(CH 2 )qC(O)NR 2 5 R 2 6 , NR 27 C(O)NR R26 (CH 2 )qNR 2 7 C(O)NR 2 5 R 26 , O(CH 2 )qNR 2 1C(O)NR 2 sR 26 , OC(O)NR R26 (CH 2 )qOC(O)NR R 26 , O(CH 2 )qOC(O)NRR26 , NR2C(O)OR24 (CH 2 )qNR 27 C(O)OR 24 , O(CH2)qNR2C(O)OR24, NR2SO2R24 (CH 2 )qNR2SO 2 R24, O(CH 2 )qNR 27 SO 2 R 24 , S0 2 NR 5 R 26 , (CH 2 )qSO 2 NR2R26, or 25 O(CH 2 )qSO 2 NR R2, or a substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl]-[alkyl or alkenyl], aryl, aralkyl, 69 WO 2008/086161 PCT/US2008/050208 aralkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group, q is 1, 2, 3, 4, 5, or 6; and each R 24 , R 5 , R 26 , and R 27 is independently hydrogen, or a 5 substituted or unsubstituted alkyl, cycloalkyl, cycloalkenyl, [cycloalkyl or cycloalkenyl)-[alkyl or alkenyl], aryl, aralkyl, arylalkenyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heteroaryl, heteroarylalkyl, or heteroarylalkenyl group; or R 2 5 and R 26 together with a nitrogen atom to which they are attached form a 3-7 membered heterocyclic ring substituted with 0-3 J 10 groups, that further comprises 0-3 additional heteroatoms selected from the groups consisting of 0, NR 7 , S, S(O), and S(0) 2 ; or bb) a group of the formula R2R13 N R14 h R 15 / N R 23 R21 15 R22 wherein g is 0-2; and h is 0-2; 12 13 14 15 2 3fndi a) R , R, R14 R", R20, R22 and R23 are as defined in (aa); 20 70 WO 2008/086161 PCT/US2008/050208 or cc) a group of the formula k R 1 2 N R 13 R 14 h g R 2 1 N R 23N R 22 5 wherein g is 0-2; and h is 0-2; R12, R13 R14, R15, R20, R2 and R2 are as defined in (c); wherein a wavy line signifies a point of attachment. 10 2. The compound of claim 1, wherein W is NR 7 . 3. The compound of claims 1 or 2, wherein X is 0. 15 4. The compound of any one of claims 1-3, wherein Y is C(0). 5. The compound of any one of claims 1-4, wherein Z is a group of the formula: R 1 2 13 RR 1 3 N R14 R20 *R23 R21 20 R22 6. The compound of any claim 5, wherein R 2 0 is fluorine. 71 WO 2008/086161 PCT/US2008/050208 7. The compound of any one of claims 1-6, wherein Z is a group of the formula: F N-+ 5 8. The compound of any one of claims 1-7, wherein Rb is H and Ra is 4 methylphenethyl, 3,4-dimethylphenethyl, 4-pyridylethyl, 4-chlorophenethyl, 3 chlorophenethyl, benzyloxy, 2,6-difluorobenzyloxy, 2,6-dichorophenyl, 3 fluorophenethyl, 2,6-difluorophenethyl, or 2,4-difluorophenethyl. 10 9. The compound of any one of claims 1-8, wherein V is C(O). 10. The compound of any one of claims 1-9, wherein K is 0. 15 11. The compound of any one of claims 1-10, wherein R" is alkyl. 12. The compound of claim 11, wherein R" is tert-butyl. 13. The compound of any one of claims 1-12, wherein M is CH 2 . 20 14. The compound of any one of claims 1-13, wherein L is C 2 H 2 , the C 2 H 2 group being either in a Z or an E configuration. 15. The compound of claim 14, wherein M is CH 2 , m is 1 and n is 1. 25 16. The compound of any one of claims 1-15, wherein p is 1. 17. The compound of any one of claims 1-16, comprising a compound of formula XI: 72 WO 2008/086161 PCT/US2008/050208 z x Rla R2a K R 1 NR2 Ra 0 0W NH N-Rb L ( XI. 18. The compound of claim 1, comprising: 5 F F N N O <0 O H NH OH NH N N H N) CN 0yN 0 0 0 / O 0 F F C1 N N N 0Q I:- 0 - H NH - H NH N N H 0 H 0 0 0 y 0 0 0 73 WO 2008/086161 PCT/US2008/050208 F F CI N 0N 0 o0 H NH H NH N N H N H N S0 O N O 0 F F F F F NFN O~ H NH H NH N N H O H O O N O O N O O 0 F F F _CII N F N C1 - H NH - H NH N N H N N N H O H O O N O N O 0 0 ;or F F N F O 0 H NH N H N 0 O YN 0 5 0 19. A pharmaceutical composition comprising a compound of any one of claims 1-18 and a suitable excipient. 74 WO 2008/086161 PCT/US2008/050208 20. A pharmaceutical combination comprising a compound of any one of claims 1-18 in a therapeutically effective dose and a second medicament in a therapeutically effective dose. 5 21. The pharmaceutical combination of claim 20 further comprising a third medicament in a therapeutically effective dose.
22. A pharmaceutical composition comprising the combination of claim 20 or 21 and a suitable excipient. 10
23. A method of treatment of a malcondition in a patient in need thereof, wherein inhibition of a hepatitis C viral protease is medically indicated, comprising administering to the patient a compound of any one of claims 1-18 or the composition of claim 19 in a therapeutically effective amount. 15
24. A method of treatment of a malcondition in a patient, the malcondition comprising a hepatitis C viral infection, comprising administering to the patient a compound of any one of claims 1-18 or the composition of claim 19 in a therapeutically effective amount. 20
25. A method of treatment of a malcondition in a patient, the malcondition comprising a hepatitis C viral infection or a condition where inhibition of a hepatitis C viral protease is medically indicated, comprising administering to the patient the pharmaceutical combination of claim 20 or 21 or the composition of 25 claim 22 in a therapeutically effective amount.
26. The use of a compound of any one of claims 1-18 or the composition of claim 19 or 22, or the combination of claim 20 or 21, for the preparation of a medicament for use in treatment of any malcondition for which inhibition of a 30 hepatitis C protease is medically indicated.
27. The use of a compound of any one of claims 1-18 or the composition of claim 19 or 22, or the combination of claim 20 or 21, for the preparation of a medicament for use in treatment of hepatitis C. 75 WO 2008/086161 PCT/US2008/050208
28. A method of preparation of a compound of claim 1, comprising contacting a compound of formula XII: R 2 a R 2 O PG 0 XN R 6 R 1 a N H P R1 0 / TK- -W-D+ M m n 5 XII with a transition metal olefin metathesis catalyst in an amount, at a temperature, and for a duration effective to form the compound of formula XIII R 2 a R 2 O O PG Z- X N R 6 YH P R 1 a N H R' 0 T--K V W-D M m n XIII 10 wherein PG is a carboxyl protecting group, then, converting PG to NRaRb to provide a compound of formula X of claim 1 wherein L is C 2 H 2 29. The method of claim 28 wherein the transition metal olefin metathesis 15 catalyst comprises benzylidene-bis(tricyclohexylphosphine)dichlororuthenium. 76
AU2008205116A 2007-01-08 2008-01-04 Macrocyclic hepatitis C protease inhibitors Abandoned AU2008205116A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88394607P 2007-01-08 2007-01-08
US60/883,946 2007-01-08
PCT/US2008/050208 WO2008086161A1 (en) 2007-01-08 2008-01-04 Macrocyclic hepatitis c protease inhibitors

Publications (1)

Publication Number Publication Date
AU2008205116A1 true AU2008205116A1 (en) 2008-07-17

Family

ID=39345472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008205116A Abandoned AU2008205116A1 (en) 2007-01-08 2008-01-04 Macrocyclic hepatitis C protease inhibitors

Country Status (8)

Country Link
US (1) US20100323953A1 (en)
EP (1) EP2111227A1 (en)
KR (1) KR20090101372A (en)
CN (1) CN101668538A (en)
AU (1) AU2008205116A1 (en)
CA (1) CA2679563A1 (en)
EA (1) EA200900969A1 (en)
WO (1) WO2008086161A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008502A1 (en) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CA2709032C (en) 2007-12-21 2016-02-23 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
EP2323981B1 (en) * 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
MX2011006244A (en) 2008-12-10 2011-06-27 Achillion Pharmaceuticals Inc New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication.
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US8362068B2 (en) 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CN103380132B (en) 2010-12-30 2016-08-31 益安药业 Phenanthridine Macrocyclohepatitis C Serine Protease Inhibitor
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
TW201309690A (en) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201490837A1 (en) 2011-10-21 2014-11-28 Эббви Инк. METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON
SI2909205T1 (en) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014075146A1 (en) * 2012-11-16 2014-05-22 Adelaide Research & Innovation Pty Ltd Macrocyclic compounds and uses thereof
JP6342922B2 (en) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
BR112015023351A2 (en) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc crystalline form of sovaprevir, pharmaceutical composition, and method for treating a disorder
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN107074852B (en) 2014-10-14 2019-08-16 生命医药有限责任公司 Dihydropyrrolopyridine inhibitors of ROR-γ
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
CN105712901B (en) * 2016-01-22 2017-07-14 成都柏睿泰生物科技有限公司 A kind of synthetic method of the nonenoic acid dicyclohexyl amine salt of 2 amino of optical activity intermediate N tertbutyloxycarbonyls 8
TWI757266B (en) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 Modulators of ror-gamma
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
EP3452492A1 (en) 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN107915672A (en) * 2016-10-09 2018-04-17 浙江九洲药物科技有限公司 A kind of preparation method for substituting isoindoline compounds
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
MA49685A (en) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc MMR gamma INHIBITORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
CN1771050A (en) * 2003-02-07 2006-05-10 益安药业 Macrocyclic inhibitors of hepatitis C serine protease
EP2143727B1 (en) * 2003-04-18 2015-01-21 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
RS20110578A3 (en) * 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd Macrocyclic carboxylic acids and acyl sulfonamides as inhibitors of hcv replication
BRPI0509467A (en) * 2004-03-30 2007-09-11 Intermune Inc macrocyclic compounds as viral replication inhibitors
WO2007001406A2 (en) * 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
KR101294467B1 (en) * 2005-07-25 2013-09-09 인터뮨, 인크. Novel macrocyclic inhibitors of hepatitis c virus replication
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Macrocylic Inhibitors Hepatitis C Virus
DE602006019323D1 (en) * 2005-10-11 2011-02-10 Intermune Inc COMPOUNDS AND METHOD FOR INHIBITING THE REPLICATION OF THE HEPATITIS C VIRUS
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors

Also Published As

Publication number Publication date
CA2679563A1 (en) 2008-07-17
CN101668538A (en) 2010-03-10
US20100323953A1 (en) 2010-12-23
EA200900969A1 (en) 2010-02-26
WO2008086161A1 (en) 2008-07-17
EP2111227A1 (en) 2009-10-28
KR20090101372A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
AU2008205116A1 (en) Macrocyclic hepatitis C protease inhibitors
US20100120716A1 (en) Macrocyclic hepatitis c serine protease inhibitors and uses therefor
WO2008070358A2 (en) N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US20090304631A1 (en) Hepatitis c serine protease inhibitors and uses therefor
WO2010033466A1 (en) Macrocyclic inhibitors of hepatitis c protease
EP1915382A2 (en) Hepatitis c serine protease inhibitors and uses therefor
EP2041156B1 (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CN104829688B (en) Macrocyclic proline derived HCV serine protease inhibitors
BRPI0714074A2 (en) macrocyclic quinoxalinyl hepatitis c virus serine protease inhibitors
CN101674844A (en) Tetrazolyl macrocyclic hepatitis C serine protease inhibitors
JP2011506329A (en) Quinoxalinyl derivatives
WO2009073713A1 (en) Oximyl macrocyclic derivatives
EP2190858A2 (en) Urea-containing peptides as inhibitors of viral replication
CN101506223B (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2009102876A1 (en) Macrocyclic inhibitors of hepatitis c protease
HK1141233A (en) Macrocyclic hepatitis c protease inhibitors
HK1132754B (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
HK1130809B (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
HK1162532A (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period